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Overview 
Part one of this thesis is a literature review concerning the relationship 
between insight and neuropsychological function among individuals with a diagnosis 
of schizophrenia.  It comprises of two sections summarising: 1) the relationship 
between insight and executive function; and 2) the relationship between insight and 
general cognitive function.  The review concludes with a discussion on the findings, 
limitations, areas for future research and the clinical implications. 
Part two is an empirical investigation into the impact of having a diagnosis of 
schizophrenia on fitness to plead in court and stand trial.  The research compared 
how individuals with a diagnosis of schizophrenia performed on a novel ecologically 
valid measure of fitness to plead (FTP) compared to a healthy control sample.  The 
research also investigated whether performance on the FTP test was associated with 
intellectual ability, memory, executive function and psychiatric symptoms.  The 
results, limitations, recommendations and clinical implications are discussed. 
Part three is a critical appraisal of the empirical investigation described in 
part two.  It highlighted two main concerns that arose over the course of the research: 
1) the construct of fitness to plead and its impact upon the development of 
standardised measures, particularly in relation to the novel FTP test that was used in 
this study; and 2) the challenges of assessing fitness to plead in individuals with a 
diagnosis of schizophrenia and whether the FTP test is applicable across the 
spectrum of schizophrenia. 
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Abstract 
Aim: This review examines the neuropsychological correlates of poor insight in 
schizophrenia which continues to be debated in the research literature. 
Method: A systematic search of the literature was conducted on studies published 
between January 2004 and August 2011.  Thirty-two studies were included in the 
review and organised into two sections: 1) the relationship between insight and 
executive function (n = 7); and 2) the relationship between insight and general 
cognitive function (n = 25). 
Results: It was found that executive function and general cognitive function are 
associated with poor insight in individuals with schizophrenia, but that the observed 
relationships are sporadic and somewhat modest.  There also does not appear to be 
consensus over how the relationship between insight and neuropsychological 
function changes over time. 
Limitations: A limitation of the review was its narrow focus on the relationship 
between neuropsychological function and insight, as it is evident that other factors 
might also relate to insight.  In addition, the studies included in the review limit the 
ability to draw conclusions and generalise the results due to inconsistent use of 
measures to assess insight and neuropsychological function, and the predominant use 
of relatively small male samples. 
Conclusions: Poor neuropsychological function is associated to insight in 
schizophrenia, but is not in itself sufficient to account for poor insight.  Therefore, 
neuropsychological function should be assessed in conjunction with other capacities 
to gain a more holistic understanding of the abilities that underpin insight. 
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Introduction 
Insight or self-awareness is a complex construct which can be conceptualised 
in various ways (Orfei, Robinson, Bria, Caltagirone & Spalleta, 2008).  This review 
focuses on the ‘clinical’ model of insight.  Insight is a term used by mental health 
professionals to describe a patient’s awareness and understanding of their illness.  
Although there is some debate over the precise definition of the term, it is commonly 
agreed that insight is a multi-dimensional construct (Baier, 2010; Dam, 2006) that 
encompasses: 1) awareness of a mental disorder; 2) awareness of specific signs and 
symptoms of the mental disorder; 3) attribution of symptoms to the mental disorder; 
4) understanding of the social consequences of the mental disorder; and 5) awareness 
of the need for treatment (Amador & David, 2004).  It is also commonly agreed that 
insight is on a continuum and can range from complete denial, to vague awareness of 
illness, to a full understanding of one’s illness (Osatuke, Ciesla, Kasckow, Zisook & 
Mohamed, 2008). 
Insight is of particular interest in patients with psychotic disorders, as lack of 
insight is frequently associated to psychosis.  Psychotic disorders are characterised 
by delusions and hallucinations and include a range of diagnoses (i.e. brief psychotic 
disorder, delusional disorder, schizoaffective disorder, schizophrenia, and 
schizophreniform disorder) that are determined based upon symptom prevalence 
(Diagnostic and Statistical Manual for Mental Disorder – Fourth Edition: American 
Psychiatric Association, 1994).  Despite the range of psychotic disorders, the 
majority of studies focus on the relationship between insight and schizophrenia, or 
insight and a combination of schizophrenia and related disorders (e.g. schizoaffective 
disorder and schizophreniform disorder).  Moreover, few studies have examined 
whether the different types of psychotic disorders show similar or dissimilar 
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relationships to insight (David, Buchanan, Reed & Almeida, 1992; David et al. 
1995).  In regards to the relationship between insight and schizophrenia, Flashman 
(2002) reported that 67% to 89% of patients with schizophrenia have poor insight 
and that poor insight is associated with non-adherence to medication (Perkins, 2002), 
higher symptom levels during treatment (Lincoln, Lüllmann & Winfried, 2007), poor 
social functioning (Rossi et al., 2000) and poor work quality and work habits 
(Giugiario et al., 2011; Lysaker, Bryson & Bell, 2002). 
There are various methods of assessing insight, some of which assess only 
one dimension of insight, while others assess multiple dimensions. Uni-dimensional 
assessments of insight include: 1) the Insight and Treatment Attitudes Questionnaire 
(ITAQ: McEvoy, Aland, Jr., Wilson, Guy & Hawkins, 1981) which measures a 
patient’s attitudes about his or her mental illness and need for treatment; and 2) the 
Positive and Negative Symptoms Scale (PANSS: Kay, Fiszbein & Opfer, 1987) 
which has a single insight sub-scale embedded in the measure.  Multi-dimensional 
assessments of insight include: 1) the Schedule for the Assessment of Insight (SAI: 
David, 1990) which measures recognition of mental illness, acknowledging unusual 
mental events as pathological and compliance with treatment; and 2) the Scale to 
Assess Unawareness of Mental Disorder (SUMD: Amador, Strauss, Yale & Flaum, 
1993) which is a semi-structured interview that evaluates multiple domains of 
insight.  Self-administered insight scales are also available and include measures 
such as the Self-Appraisal of Illness Questionnaire (SAIQ: Marks, Fastenau, Lysaker 
& Bond, 2000), the Davidhizar Insight Scale (DIS: Davidhizar, 1987) and the Insight 
Scale (IS: Birchwood, Smith, Drury & Healy, 1994).  Evidence for the concurrent 
validity of self-report and clinician-rated scales varies.  Marks et al. (2000) found 
concurrent validity between a self-report and clinician-rated scale, whereas Young, 
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Campbell, Zakzanis and Weinstein (2003) found a discrepancy between the two 
types of measure.  Jovanovski, Zakzanis, Atia, Campbell and Young (2007a) 
counterbalanced administration of measures and found that self-report and clinician-
rated scales were associated if the self-report measure was administered prior to the 
clinician-rated scale, but not vice versa. 
Reasons for lack of insight in schizophrenia continue to be debated in the 
research literature.  A review by Chakraborty and Basu (2010) produced a 
comprehensive summary of models of insight, including deficits in insight being 
caused by clinical aspects of illness (e.g. positive symptoms, negative symptoms and 
disorganised symptoms), defence mechanisms, misattribution errors, impaired 
metacognition, sociocultural processes, individual differences and 
neuropsychological deficits.  Lysaker, Buck, Salvatore, Popolo and Dimaggio (2009) 
also discussed how lack of insight might arise due to the construction of personal 
narratives rather than an inability to grasp or accept the ‘truth’ as offered by mental 
health professionals. 
A systematic review by Cooke, Peters, Kuipers and Kumari (2005) found: 1) 
little support for the ‘clinical model’ of insight which posits that poor insight is a 
symptom of a disease process; 2) some evidence for the ‘psychological denial model’ 
of insight which posits that poor insight results from attempts to reduce distress by 
using denial as a coping strategy; and 3) the majority of evidence for the 
‘neuropsychological model’ of insight which posits that poor insight results from 
deficits in neurocognition and is related to frontal lobe dysfunction. 
The neuropsychological model of insight arose due to the parallels between 
poor insight in individuals with psychosis and poor insight in individuals with brain 
lesions (Amador & David, 2004).  For example, frontal lobe damage is characterised 
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by cognitive and behavioural impairments that the patient lacks awareness and 
concern for.  This lack of awareness for cognitive deficits has similarly been 
observed in patients with schizophrenia (Medalia & Thysen, 2008) and the frontal 
lobes have also been identified as a key area of dysfunction in individuals with 
schizophrenia (Dibben, Rice, Laws & McKenna, 2009). 
In regards to neuropsychological deficits, the association between insight and 
neuropsychological functioning in individuals with schizophrenia remains unclear 
(McCabe, Quayle, Beirne & Duane, 2002; Pia & Tamietto, 2006).  Numerous studies 
have found a relationship between insight in schizophrenia and executive function 
(Buckley, Hasan, Friedman & Cerny, 2001; Drake & Lewis, 2003; Light & Braff, 
2002; Lysaker, Bell, Bryson & Kaplan, 1998; Lysaker & Bell, 1994; Mohamed, 
Fleming, Penn & Spaulding, 1999; Smith, Hull, Israel & Willson, 2000; Young et al., 
1998) and general cognitive function, such as memory and attention (Cuesta & 
Peralta, 1994; Keshavan, Rabinowitz, DeSmedt, Harvey & Schooler, 2004; Laroi et 
al., 2000).  However, there are also numerous studies which suggest there is no 
relationship between insight and executive function (Kemp & David, 1996; Sanz, 
Constable, Lopez-Ibor, Kemp & David, 1998) or general cognitive function (Carroll 
et al., 1999) and that insight is associated with other factors such as psychopathology 
(Collins, Remington, Coulter & Birkett, 1997; Mintz, Dobson & Romney, 2003), 
theory of mind (Langdon & Ward, 2009), metacognition (Gilleen, Greenwood & 
David, 2011) or social cognition and perceptual organisational capacities (Lysaker et 
al., 2007).  Other studies also suggest there is a curvilinear relationship between 
insight and neuropsychological deficits (Startup, 1996).  The inconsistencies between 
these studies might be due to methodological differences such as different: sample 
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groups; working definitions of insight; measures of insight and cognitive function; 
and different statistical analysis methods. 
A systematic review by Shad, Tamminga, Cullum, Haas and Keshavan 
(2006) examined the relationship between insight and executive functioning in 
schizophrenia and found that out of the 34 studies reviewed, 21 reported associations 
between deficits in at least one dimension of insight and a measure of executive 
function. 
A broader meta-analysis by Aleman, Agrawal, Morgan and David (2006) 
examined the relationship between insight and general neuropsychological function 
in patients with psychotic disorders.  The authors found a small, but statistically 
significant, positive relationship between insight and general cognitive function 
which suggests that poor insight can, to some extent, be explained by 
neuropsychological deficits.  More specifically, in patients with general psychotic 
disorders, a stronger association was found between insight and executive function, 
compared to the association between insight and intellectual function.  However, this 
trend was not present in samples of patients with a diagnosis of schizophrenia, which 
might be due to patients with schizophrenia experiencing more profound intellectual 
difficulties in comparison to those with general psychotic disorders. 
This literature review aims to examine studies that explored the relationship 
between insight and neuropsychological functioning in schizophrenia that were 
published after the systematic reviews by Shad et al. (2006) and Aleman et al. 
(2006).  The review question is: In individuals with a diagnosis of schizophrenia, is 
insight associated with: 1) executive function; and/or 2) general cognitive function? 
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Method 
Search strategy 
An initial scoping search was conducted using Google Scholar to identify 
relevant search terms.  Search terms were also identified by referring to search 
strategies used in previous systematic reviews and relevant keywords in past studies.  
Relevant search terms included: insight, awareness, psychosis, schizophrenia, 
cognitive function and neuropsychological function. 
The MetaLib search engine was then used to identify the databases which 
generated the most relevant studies for this review using the search terms.  The four 
databases that generated the largest number of studies were: Embase, Medline, 
Psycinfo and Web of Science.  Each of these four databases was then individually 
searched using multiple search combinations that included the following search 
terms: schizophren* or psychosis; and insight or awareness or unawareness; and 
cogniti* or neuropsycholog* or memory or intelligence. 
The broad search strategy generated large numbers of studies (Embase = 850, 
Medline = 498, Psycinfo = 297 and Web of Science = 826), many of which were 
duplicated across searches or irrelevant.  Nevertheless, multiple search terms and 
combinations were necessary due to the vast variation in terminology used in the 
literature. 
 
Study selection 
Relevant studies (i.e. those that met all the inclusion criteria) were selected by 
reviewing titles, then abstracts and full articles if necessary.  The inclusion criteria 
included: 1) adults diagnosed with a psychotic disorder (e.g. brief psychotic disorder, 
delusional disorder, schizoaffective disorder, schizophrenia, or schizophreniform 
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disorder) based on the Diagnostic and Statistical Manual of Mental Disorders – 
Fourth Edition or the International Classification of Diseases – Tenth Edition; 2) 
reports standardised measures of insight or awareness (e.g. the Insight and Treatment 
Attitudes Questionnaire, the Schedule for the Assessment of Insight, the Scale to 
Assess Unawareness of Mental Disorder, or the Insight Scale); 3) reports 
standardised measures of cognitive function (e.g. the Wisconsin Card Sorting Test, 
the Trail Making Test, the Wechsler Adult Intelligence Scale, or the Wechsler 
Memory Scale); 4) utilises empirical methodologies, namely cross-sectional and 
longitudinal correlational designs, to investigate the relationship between insight and 
cognitive function; 5) published between January 2004 and August 2011; 6) 
published in a peer-reviewed journal; and 7) published in English.  Studies that 
reported only brain imaging findings in relation to insight were excluded from this 
review. 
Based on the search strategy and the study selection process, 32 studies were 
included in this review.  All these studies were systematically reviewed by tabulating 
information regarding the study design, sample, measures and results. 
 
Results 
The 32 studies identified are considered below in two sections: 1) the 
relationship between insight and executive function; and 2) the relationship between 
insight and general cognitive function. 
 
Relationship between insight and executive function 
Seven studies examined the relationship between insight and executive 
function in patients with a diagnosis of schizophrenia (Table 1). 
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Table 1 
The relationship between insight and executive function 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Simon, 
Berger, 
Giacomini, 
Ferrero & 
Mohr (2006) 
Design: Cross-sectional 
 
Sample: 38 schizophrenia; 
Age = 24.7 years (SD = 
6.4); Illness duration = 62.0 
months (SD = 63.0) 
 
CDS 
PANSS 
SUMD BADS 
NART 
Stroop 
TMT 
VFT 
WCST 
(computerised)  
 
Insight into mental disorder, social 
consequences and symptom attribution are 
associated with letter fluency. 
Association is mediated by depressive 
symptoms. 
In regression analysis anti-psychotic 
dosage was predictive of insight. 
 
Lysaker, 
Whitney & 
Davis 
(2006) 
Design: Cross-sectional 
 
Sample: 29 schizophrenia 
& 24 schizoaffective 
disorder; Age = 47.5 years 
(SD = 9.1) 
PANSS SUMD D-KEFS Insight into mental disorder and need for 
treatment are associated with executive 
function (i.e. inhibition, flexibility of 
thought, planning ahead, completing tasks 
of increasing complexity and the ability to 
use context to aid understanding). 
In regression analysis symptomatology and 
inhibition switching (executive function) 
were predictive of insight. 
 
Jovanovski, 
Zakzanis, 
Young & 
Campbell 
(2007b) 
Design: Cross-sectional 
 
Sample: 21 schizophrenia; 
Age = 49.6 (SD = 9.5); 
Illness duration = 24.3 
years (SD = 7.8); 
Predominantly male 
 
BDI 
BPRS 
SUMD BADS 
WAIS (vocabulary & 
matrix reasoning) 
Insight into social consequences is 
associated with ability to identify and shift 
between simple and complex rules. 
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Table 1 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Raffard et 
al. (2009) 
Design: Cross-sectional 
 
Sample: 50 schizophrenia 
& 10 schizoaffective 
disorder; Age = 33.4 years 
(SD = 9.5); Illness duration 
= 10.4 years (SD = 9.8) 
 
BDI 
STAI 
SUMD 
 
NART 
TAP 
Poor insight into medication and social 
consequences is associated with poorer 
working memory, more errors and 
omissions. 
Poor insight into social consequences is 
also associated with poorer inhibition and 
divided attention. 
Mysore et 
al. (2007) 
Design: Cross-sectional 
 
Sample: 56 schizophrenia; 
Age = 35.0 (SD = 10.0); 
Illness duration = 10.5 
years (SD = 8.5); 
Predominantly male 
 
SANS 
SAPS 
SAI HVLT-R 
NART 
WCST 
Poor insight is associated with more 
perseverative errors. 
Insight is not associated with working 
memory. 
Simon, De 
Hert, 
Wampers, 
Peuskens & 
van Winkel 
(2009) 
Design: Cross-sectional 
 
Sample: 132 schizophrenia; 
Age = 29.7 years (SD = 
8.9) 
PECC 
 
PECC TMT 
WAIS (letter number 
sequencing) 
WCST 
Awareness of having a mental illness 
(AMI) is associated with preservative 
errors.  Perseverative errors explained 
7.9% of the variance in AMI. 
Symptomatology explained 20% of 
variance in AMI. 
Awareness of having symptoms attributed 
to a mental illness (ASAMI) is not 
associated with executive function. 
Symptomatology explained 16.5% of 
variance in ASAMI. 
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Table 1 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Barrera, 
McKenna & 
Berrios 
(2009) 
Design: Cross-sectional 
 
Sample: 31 schizophrenia; 
Age = 40.0 years (SD = 
8.9)  
CASH 
FTD 
IS BADS (six elements) 
BPV 
CAWS 
Camel and cactus test 
CET 
Graded naming 
HB 
 
Insight is associated with graded naming 
test and symptoms of reality distortion. 
ote. BADS, Behavioural Assessment of the Dysexecutive Syndrome; BDI, Beck Depression Inventory; BPRS, Brief Psychiatric Rating Scale; BPV, British Picture Vocabulary scale; CASH, 
The Comprehensive Assessment Schedule History; CAWS, Concrete and Abstract Word Synonym Test; CDS, Calgary Depression Scale; CET, Cognitive Estimates Test; D-KEFS, Delis-
Kaplan Executive Function System; FTD, Formal Though Disorder scale; HB, Hayling and Brixton test; HVLT-R, Hopkins Verbal Learning Test-Revised; IS, Insight Scale; NART, National 
Adult Reading Test; PANSS, Positive and Negative Syndrome Scale; PECC, Psychosis Evaluation tool for Common use by Caregivers; SAI, Schedule for the Assessment of Insight; SANS, 
Schedule for the Assessment of Negative Symptoms; SAPS, Schedule for the Assessment of Positive Symptoms; STAI, Spielberger State Trait Anxiety Inventory; SUMD, Scale to Assess 
Unawareness of Mental Disorder; TAP, Test for Attentional Performance; TMT, Trail Making Test; VFT, Verbal Fluency Task; WAIS, Wechsler Adult Intelligence Scale; WASI, Wechsler 
Abbreviated Scale of Intelligence; WCST, Wisconsin Card Sorting Test 
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Simon, Berger, Giacomini, Ferrero and Mohr (2006) administered the Scale 
to assess Unawareness of Mental Disoders (SUMD) to investigate the relationship 
between insight and multiple measures of executive function on 38 inpatients with 
schizophrenia.  The authors concluded that executive function is only weakly 
associated with insight, as only one measure of executive function (letter fluency) 
was associated with a composite of score of insight (i.e. an awareness of a mental 
disorder and its social consequences and misattribution for symptoms), where better 
performance on the letter fluency task was associated with better insight.  This 
correlation remained significant when controlling for positive and negative 
symptoms of schizophrenia, but not for depressive symptoms, which suggests the 
relationship between insight and executive functioning might be mediated by 
depressive symptoms.  When carrying out regression analysis, only anti-psychotic 
medication dosage was predictive of insight into the need for treatment.  Only partial 
associations between insight and executive function might be indicative that insight 
is a multi-dimensional phenomenon.  A limitation of this study was that only patients 
with resolved symptoms and discharge plans were included in the study and 
therefore results cannot be generalised to patients with more acute symptoms. 
Lysaker, Whitney and Davis (2006) administered a shortened version of the 
SUMD and the Delis-Kaplan Executive Function System (D-KEFS) to explore the 
relationship between insight and executive function, respectively, in 53 outpatients 
with schizophrenia spectrum disorders.  Insight into having a disorder and the need 
for treatment was associated with Colour-Word, Tower and Word Context scores.  
Insight into having a disorder was also related to Verbal Fluency.  These findings 
suggest that insight is related to capacity to shift attention, inhibition, flexibility of 
thought, planning ahead, completing tasks of increasing complexity and the ability to 
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use context to aid understanding.  A strength of the study was that the raters who 
conducted the SUMD were blind to the D-KEFS scores.  However, as only three sub-
scales of the SUMD were used to measure insight, it is not known how awareness of 
specific signs and symptoms of the disorder or attribution of symptoms to a disorder 
relate to executive function. 
Similarly to Lysaker et al. (2006), Jovanovski, Zakzanis, Young and 
Campbell (2007b) utilised the SUMD to measure insight, but used the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS) to measure executive 
functioning.  Correlations revealed that, in a sample of 21 outpatients with a 
diagnosis of schizophrenia, insight into the social consequences of mental disorder 
was associated with the ability to identify and shift between simple and complex 
rules which is a type of executive function.  Prior to controlling for IQ, insight into 
the social consequences of mental disorder was associated with the ability to make 
sensible estimates of time needed to perform different activities.  However, the 
results of this study need to be interpreted with caution as statistical corrections for 
multiple correlations was not carried out due to its small sample size and therefore 
the probability of making Type I errors is increased. 
A larger outpatient sample of 60 participants with schizophrenia was 
recruited by Raffard et al. (2009) to explore the relationship between insight and 
executive function.  Insight was assessed using the SUMD, whilst executive function 
was assessed using the Test for Attentional Performance (TAP), which divides 
executive functioning into four processes: Updating; Shifting; Inhibition; and 
Divided Attention.  Findings suggest that poor insight in schizophrenia is partially 
related to executive dysfunction, as insight into the need for medication and the 
social consequences of the disorder were related to poorer working memory 
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(Updating) and more errors and omissions.  Insight into the social consequences was 
also related to poorer inhibition and divided attention.  A strength of the study was 
that confounding variables such as processing speed, medication and 
symptomatology were also examined and controlled for because they were 
significantly correlated to insight. 
Using a different measure of insight, Mysore et al. (2007) also investigated 
the association between insight and executive functioning.  The authors divided 
participants into three groups according to level of insight into illness and ability to 
attribute experiences as symptoms of their illness as measured by the Schedule for 
Assessment of Insight (SAI).  The three groups did not differ in terms of age, 
education or duration of illness.  Results showed that participants in the ‘unaware’ 
group (n = 18) made more perseverative errors (i.e. inappropriate and unintentional 
repetition of a response despite a change in the stimulus) on the Wisconsin Card 
Sorting Test (WCST) than the ‘aware, correct attributers’ group (n = 24) and the 
‘aware, incorrect attributers’ group (n = 14), which indicates lack of awareness is 
related to greater executive impairment.  However, no difference was observed 
between the three groups in relation to working memory.  A limitation of the study 
was the sample composition, as it mainly consisted of male participants.  In addition, 
not all participants were taking anti-psychotic medication and impact of different 
levels of medication on performance is not known. 
Over a six-year period, Simon, De Hert, Wampers, Peuskens and van Winkel 
(2009) recruited 132 inpatients with schizophrenia spectrum disorders to measure the 
association between executive functioning, working memory and insight using the 
Psychosis Evaluation tool for Common use by Caregivers (PECC).  The PECC 
measures two dimensions of insight: awareness of having a mental illness (AMI) and 
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awareness of having symptoms attributed to a mental illness (ASAMI).  After 
corrections for multiple comparisons, performance on only one measure of executive 
function, the WCST ‘categories completed,’ correlated with AMI which suggests 
that executive function only somewhat relates to insight.  Lack of association 
between insight and other measures of executive function might have arisen as 
insight was rated by caregivers and not self-report.  In addition, despite having a 
large sample size, the authors acknowledge a wide range of actual levels of symptom 
severity amongst the sample population which might explain why symptom severity 
accounted for 20% of the variance in AMI. 
A study by Barrera, McKenna and Berrios (2009) did not find any 
associations between multiple measures of executive function and insight as 
measured by the Insight Scale (IS), which is a self-report scale that assesses 
recognition of being unwell and acknowledgment of the need for help.  The results 
did show an association between insight and reality distortion which is a symptom of 
schizophrenia.  In addition, a correlation was found between insight and semantic 
ability on the graded naming test where participants are asked to name pictures of 
objects and animals, which suggests that impaired access to semantic knowledge 
might be associated with reduced insight.  However, the sample size in this study 
was small and therefore effects might not have been detected. 
  
Summary 
These seven studies suggest the relationship between insight and executive 
function among individuals with a diagnosis of schizophrenia is complex as, 
although six of the seven studies found an association between at least one dimension 
of insight and executive function, these associations varied between studies. 
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Three out of these seven studies explored the relationship between different 
measures of executive function and a composite score of insight, whilst the 
remaining four studies investigated the relationship between different measures of 
executive function and sub-dimensions of insight.  A possible reason for examining 
the relationship between several measures of executive function and sub-dimensions 
of insight is that evidence suggests that both constructs are multi-dimensional and 
that a complex relationship might exist between the two variables where only some 
aspects of each construct relate to one another.  However, the theoretical basis for 
why particular aspects of each construct might be associated together is not known. 
Of the three studies that explored the relationship between different measures 
of executive function and a composite score of insight, two found a relationship 
between insight and executive function (i.e. letter fluency and perseveration errors), 
whilst one did not find a relationship between insight and executive function, but 
found a relationship between insight and semantic ability. 
Of the four studies that investigated the relationship between different 
measures of executive function and sub-dimensions of insight, the results are also 
mixed.  In regards to insight into having a mental disorder, two out of these four 
studies found an association with executive function (i.e. verbal fluency, inhibition, 
planning and attention), whilst two studies found no relationship.  In regards to 
insight into the need for treatment, two out of these four studies found an association 
with executive function (i.e. capacity to shift attention, planning ahead, completing 
tasks of increasing complexity and the ability to use context to aid understanding), 
whilst the other two studies showed no association.  Regarding insight into the social 
consequences of the mental disorder, two out of these four studies found an 
association with executive function (i.e. working memory, divided attention, 
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inhibition, making sensible estimates of time and ability to identify and shift rules), 
whilst the other two studies found no association.  Finally, insight into the specific 
signs and symptoms of the disorder was not assessed in any of these four studies, and 
only one out of these four studies investigated the relationship between insight into 
the attribution of symptoms to disorder and executive function, but found no 
association with executive function. 
In regards to whether executive function is predictive of insight, only three 
out of the seven studies performed regression analysis.  Two of these three studies 
found that executive was predictive of insight, but only weakly, whilst one study 
found that executive function was associated with insight but not predictive of 
insight.  In addition to the limited predictive ability of executive function, these 
studies would suggest that other variables such as symptomatology are associated 
with insight and that executive function alone cannot account for degree of insight.  
One study also suggested that the relationship between insight and executive function 
is mediated by depression. 
The marked variation in results might be due to methodological differences 
and therefore should be interpreted cautiously.  Firstly, the measures used to assess 
insight and executive function were not consistent across studies and thus 
comparison is difficult.  Insight was most commonly assessed by a multi-
dimensional clinician-rated scale, the SUMD, but was also measured by caregiver-
report and self-reports.  Executive function was measured by numerous tests 
including the BADS, WCST and D-KEFS.  Secondly, sample characteristics limited 
the ability to generalise findings as the majority of studies had a small sample size of 
predominantly male participants.  Thirdly, all seven studies used a cross-sectional 
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design, which limits the ability to generalise the findings to the wider population of 
individuals diagnosed with schizophrenia. 
Overall, evidence would suggest that executive function is, to some extent, 
associated with level of insight.  However, the variation in association levels would 
suggest that this relationship is not simple and executive function cannot solely 
account for degree of insight.  Therefore, the next section of this review goes on to 
explore the relationship between insight and other aspects of general cognitive 
function. 
 
Relationship between insight and general cognitive function 
Twenty-five studies examined the relationship between insight and general 
cognitive function in patients with a diagnosis of schizophrenia.  These studies were 
further sub-divided into two sections based on length of diagnosis: a) recent-onset 
schizophrenia; and b) chronic schizophrenia. 
 
The relationship between insight and general cognitive function in patients with 
recent-onset schizophrenia 
This section includes eight studies that examined the relationship between 
insight and general cognitive function in patients with recent-onset schizophrenia 
(Table 2). 
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Table 2 
The relationship between insight and general cognitive function in patients with recent-onset schizophrenia 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Subotnik et 
al. (2005) 
Design: Cross-sectional 
 
Sample: 52 schizophrenia, 
9 schizoaffective disorder 
& 8 schizophreniform; Age 
= 24.7 years (SD = 5.3) 
 
BPRS 
MMPI 
SUMD CPT Patients in remission: Insight into mental 
disorder/attributing symptoms to mental 
disorder is associated with focused/ 
sustained attention that requires 
immediate/working memory. 
Acutely psychotic patients: Insight into 
mental disorder/effects of treatment is 
associated with psychological defences. 
 
Mutsatsa, 
Joyce, 
Hutton, and 
Barnes 
(2006) 
Design: Prospective cross-
sectional 
 
Sample: 94 schizophrenia; 
Age = 23.5 years (SD = 
10.8); Predominantly male 
 
MADRS 
SANS 
SAPS 
SFS 
SAI CANTAB 
NART 
WAIS 
Insight is associated with: 1) spatial 
working memory; 2) negative symptoms 
and; 3) depression. 
In regression analysis, cognitive function 
was not predictive of insight. 
Lepage et al. 
(2008) 
Design: Cross-sectional 
 
Sample: 30 schizophrenia, 
7 schizoaffective disorder, 
1 schizophreniform, 1 
delusional disorder, 3 
bipolar disorder, 5 not 
otherwise specified & 4 
unavailable; Age = 23.2 
years (SD = 3.8) 
 
CDSS 
HAS 
SANS 
SAPS 
BCIS 
PANSS  
SUMD 
 
FFTSI 
Hinting task 
TA 
TMT 
Tower of London 
WAIS 
WMS 
 
Clinical insight is not associated with 
cognitive function. 
Cognitive insight is associated with verbal 
learning and memory. 
Please note: MRI scans were conducted, 
but will not be discussed. 
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Table 2 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Morgan et 
al. (2010) 
Design: Cross-sectional 
 
Sample: 39 schizophrenia, 
6 schizoaffective disorder, 
10 depressive psychosis & 
10 other psychosis; 91 
control group; Age = 27.2 
years (SD = 7.9)   
 
SCAN SAI-E AVLT 
LNS 
NART 
RCPM 
VF 
TMT 
WAIS 
WMS 
Insight is associated with performance IQ and 
verbal learning. 
Please note: Voxel-based magnetic resonance 
imaging scans were conducted, but will not be 
discussed. 
Quee et al. 
(2011) 
Design: Cross-sectional 
 
Sample: 270 non-affective 
psychosis; Age = 27.7 years 
(SD = 6.5); Predominantly 
male 
GAF 
PANSS 
IS 
PANSS 
Performance Test 
Response Set Shifting 
WAIS 
 
Insight is associated with composite 
neurocognitive score, social cognition and 
clinical symptoms.   
In regression analysis, neurocognitive score 
was not predictive of insight when adding 
clinical symptoms. 
Phase of illness moderates the relationship 
between insight and 3 variables.  
  
Mintz, 
Addington 
and 
Addington 
(2004) 
Design: Prospective 
longitudinal  
 
Sample: 180 schizophrenia 
spectrum disorder; Age = 
24.5 years (SD = 8.4); 
Predominantly male 
CDSS 
PANSS 
PANSS CFT 
COWAT 
CROP 
Grooved pegboard 
LNS 
RAVLT  
ROCF 
SPAN 
TMT 
WCST 
WMS 
Insight is not associated to cognition or 
demographics at any time point.   
Insight is associated to higher depression at 
baseline and less severe positive and negative 
symptoms at baseline, 3, 6 and 12 months.  
Insight significantly improved over the 12-
month period, where the most improvement 
occurred in the first 3 months. 
27 
Table 2 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Saeedi, 
Addington 
and 
Addington 
(2007) 
Design: Prospective 
longitudinal 
 
Sample: 278 psychosis; 
Age = 24.4 years (SD = 
8.0); Predominantly male 
CDSS 
PANSS 
QLS 
PANSS CFT 
COWAT 
Grooved pegboard 
LNS 
RAVLT 
ROCF 
SPAN 
TMT 
WCST 
WMS 
 
Insight associated with cognitive function 
at 1-year. 
Insight associated with depression at 
baseline. 
Insight associated with psychopathology 
and social function at all time points (i.e. 
baseline, 1-, 2- and 3- years). 
Overall, insight improved over 1-year. 
 
McEvoy et 
al. (2006) 
Design: Longitudinal 
 
Sample: 148 schizophrenia, 
26 schizoaffective disorder, 
77 schizophreniform 
disorder; Age = 23.9 (SD = 
4.7); Predominantly male 
CDSS 
CGI-S 
MADRS 
ITAQ CPT 
COWAT 
CVLT 
Letter Number 
Sequencing 
NART 
TMT 
WAIS 
WCST 
WMS  
 
Insight not associated with cognition or 
demographics at any time point. 
Insight associated with depression at 
baseline. 
Insight associated with positive and 
negative symptoms at baseline, 3-, 6- and 
12-months.  
Overall, insight improved over 12-months, 
where the most improvement occurred in 
the first 3 months. 
 
ote. AVLT, Auditory Verbal Learning Test; BCIS, Beck Cognitive Insight Scale; BPRS, Brief Psychiatric Rating Scale; CANTAB, Cambridge Neuropsychological Test Automated Battery; 
CDSS, Calgary Depression Scale for Schizophrenia; CFT, Category Fluency Test; CGI-S, Clinical Global Impressions-Severity Scale; COWAT, Controlled Oral Word Association Test; CPT, 
Continuous Performance Test; CROP, Copy of Rey-Osterrieth picture; CVLT, California Verbal Learning Test; FFTSI, Four-Factor Tests of Social Intelligence; HAS, Hamilton Anxiety Scale; 
IS, Insight Scale; LNS, Letter-Number Span; MADRS, Montgomery-Asberg Depression Rating Scale; MMPI, Minnesota Multiphasic Personality Inventory; NART, National Adult Reading 
Test; PANSS, Positive and Negative Syndrome Scale; RAVLT, Rey Auditory Verbal Learning Test; RCPM, Ravens Coloured Progressive Matrices; ROCF, Rey–Osterrieth Complex Figure 
test; SAI, Schedule for the Assessment of Insight; SANS, Schedule for the Assessment of Negative Symptoms; SAPS, Schedule for the Assessment of Positive Symptoms; SCAN, Schedules for 
Clinical Assessment in Neuropsychiatry; SFS, Social Function Scale; SPAN, Span of Apprehension; SUMD, Scale to Assess Unawareness of Mental Disorder; TA, Test of Attention; TMT, 
Trail Making Test; VF, Verbal Fluency; WAIS, Wechsler Adult Intelligence Scale; WCST, Wisconsin Card Sorting Test; WMS, Wechsler Memory Scale 
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Subotnik et al. (2005) explored the relative contributions of cognitive 
function and psychological defensiveness as predictors of insight, as measured by the 
SUMD, in 52 outpatients with recent-onset schizophrenia.  In patients whose 
psychosis was in remission (n = 29), insight into mental disorder and attributing 
symptoms to mental disorder was associated with poor target discrimination in a task 
that required immediate or working memory for sustained attention.  Insight into the 
effects of treatment was also associated with focused, sustained attention.  However, 
in patients who were acutely psychotic (n = 23), higher psychological defensiveness, 
particularly related to social acquiescence and presenting oneself in a socially 
desirable light, was associated with poorer insight into mental disorder and the 
effects of treatment whilst cognitive measures were not predictive of insight.  A 
strength of this study was exploring the effect of illness severity upon the 
relationship between insight and cognitive function by comparing acutely psychotic 
participants with those in remission.  However, the authors acknowledged the need 
for replication of the study due to the relatively small sample size. 
Mutsatsa, Joyce, Hutton and Barnes (2006) carried out a study on 94 patients 
with first-episode schizophrenia.  The authors measured insight, clinical symptoms, 
cognitive function and social function.  Their findings suggest that poor global 
insight correlated with poorer spatial working memory, which is a facet of executive 
functioning.  Poor global insight also correlated with more severe negative symptoms 
and disorganisation, but less severe depressive symptoms.  Trends were also 
observed between global insight and current IQ and IQ change score.  Selection bias 
might have impacted the results as only 74 out of 94 patients underwent 
neuropsychological testing and it was found that patients with poorer insight, but 
better social functioning, were less likely to have undertaken neuropsychological 
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testing.  Another limitation was that, despite aiming to compare how insight differs 
between patients with first-episode schizophrenia and established schizophrenia, the 
authors did not recruit a comparison group to test this hypothesis. 
A study by Lepage et al. (2008) also recruited patients with first-onset 
psychosis and administered two clinician-rated measures of clinical insight and one 
self-report measure of cognitive insight.  Clinical insight was defined as an 
awareness of the need to treat a mental illness and cognitive insight was defined as 
the capacity to reflect on distorted beliefs and misinterpretations.  A battery of 
cognitive tests was also administered within around six weeks of beginning 
treatment.  Clinical insight was not found to correlate with any of the cognitive tests.  
Cognitive insight was found to be associated with verbal learning and memory, 
which suggests that ability to reflect on one’s cognitions, might depend on capacity 
to retrieve memories.  A limitation of the study was that not all participants 
completed the neuropsychological tests as they either refused or were unable to 
complete the tasks.  In addition, although the three insight measures correlated with 
one another, the two clinical insight scales were administered on average 17.8 days 
later than the cognitive insight scale which could have impacted the relationship 
between insight and cognition, as insight level can fluctuate during first-onset 
psychosis. 
Morgan et al. (2010) recruited 82 consecutively presenting patients with a 
diagnosis of first-onset psychosis from an epidemiological study.  The study focused 
on examining insight, as measured by semi-structured interviews using the Schedule 
for the Assessment of Insight – Expanded version (SAI-E), in relation to 
neuropsychological function and brain structure. After adjusting for multiple 
comparisons, total insight correlated with verbal learning and performance IQ on the 
30 
Wechsler Adult Intelligence Scale (WAIS).  Symptom relabelling, a component of 
insight that encompasses the ability to identify and attribute prominent symptoms of 
psychosis as pathological also correlated with performance IQ.  Further analysis 
showed that a sub-group of participants with no symptom relabelling ability (n = 20) 
scored significantly lower than participants with some symptom relabelling ability (n 
= 64) on current IQ, verbal fluency, verbal learning and set-shifting.  Overall, these 
results suggest that total insight and a sub-component of insight, symptom 
relabelling, are at least partly dependent on good overall cognitive function. 
Although the study had a large sample size, a limitation of the study was the cross-
sectional design of the study which limits the ability to generalise the results to 
patients with different durations or severity of illness. 
Quee et al. (2011) also carried out a cross-sectional design study to 
investigate the relationship between insight and cognitive function, social cognition 
and clinical symptoms.  However, they included 270 participants with differing 
phases of illness including recent-onset psychosis (n = 57) and chronic/multiple 
episodes of psychosis (n = 210).  Three of the participants included in the study had 
an unknown phase of illness.  A composite score of insight was derived from a self-
report and clinician-rated scale as the two measures of insight were highly correlated.  
A composite score of cognitive function was also obtained from seven measures of 
cognitive function that included tests of attention, processing speed, set-shifting, 
reasoning, problem solving, verbal learning and memory.  Phase of illness was found 
to moderate the relationship between insight and cognitive function, social cognition 
and clinical symptoms, where the three variables were predictive of insight in 
patients with chronic/multiple episodes of psychosis, but not in patients with recent 
onset psychosis.  A limitation of the study was that the use of composite scores of 
31 
insight and cognitive function meant that detailed interpretation of the relationship 
between the different levels of insight and cognitive function could not be carried 
out.  A strength of this study was the large sample of participants who were included 
in the study.  However, the sample largely consisted of patients with chronic/multiple 
episodes of psychosis rather than recent-onset psychosis. 
To improve the ability to generalise the results Mintz, Addington and 
Addington (2004) carried out a prospective longitudinal study exploring the 
relationship between insight and cognition in patients with first-episode psychosis 
consecutively admitted for treatment.  Insight was assessed on admission and after 
three, six and 12 months.  Of the 253 individuals admitted to hospital, 73 individuals 
did not complete the 12 month assessment for various reasons such as, non-English 
speaking, failed to attend the assessment, dropped out of the program or changed 
diagnosis.  Insight was observed to improve over the 12 month period and correlated 
with positive symptoms, negative symptoms and depression at admission, but not 
with cognitive function at any time point.  Improvement in level of insight might 
have occurred due to patients receiving a range of cognitive-behavioural and other 
psychosocial interventions over the 12 months.  However, the impact of these 
interventions was not investigated further.  The authors note that a limitation of the 
study was that they used a uni-dimensional measure of insight embedded in the 
Positive and Negative Syndrome Scale (PANSS), which could have reduced chances 
of finding a relationship between insight and cognitive function as insight is 
conceptualised as a multi-dimensional construct. 
Using the same prospective cohort as Mintz et al. (2004), Saeedi, Addington 
and Addington (2007) followed up patients at one, two and three years after 
admission.  Insight improved between baseline and one-year follow up.  At baseline 
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(n = 278), good insight was associated with higher depressive symptoms, good social 
functioning and less severe psychopathology, but not cognitive function.  At one-
year follow-up (n = 190), good insight was associated with less severe 
psychopathology, good social functioning and better immediate and delayed verbal 
memory, category fluency, WCST categories and perseverative errors and trail 
making.  At two-year follow up (n = 190) and three-year follow-up (n = 145), good 
insight was associated with less severe psychopathology and good social functioning.  
A limitation of the study was that despite documenting reasons for attrition, it is not 
known whether the participants who returned for follow-up differed significantly 
from participants who dropped out.  In addition, similarly to the study by Mintz et al. 
(2004), the impact of cognitive-behavioural and other psychosocial interventions 
upon insight, psychopathology, social functioning and cognitive function is not 
known and warrants further investigation. 
A study by McEvoy et al. (2006) carried out a two-year randomised, double-
blind clinical trial that focused on comparing the effectiveness of olanzapine 
compared with haloperidol in 263 patients experiencing a first episode of 
schizophrenia.  They also assessed the relationships between insight and cognitive 
function, psychopathology, brain volumes and co-morbid depression.  Insight 
improved significantly over the course of the study and greater insight was 
associated with older age, female gender, white ethnicity, better cognitive function, 
larger brain volume, longer time to medication non-adherence and higher levels of 
depression.  Reduced insight was also associated with higher positive and negative 
psychopathology scores.  This study benefited from a large sample size and 
longitudinal design. 
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Summary 
This section included eight studies that investigated the relationship between 
insight and cognitive function in patients with recent-onset schizophrenia.  Five of 
these eight studies used a cross-sectional design and the other three used a 
longitudinal design. 
Of the five cross-sectional design studies: two of these studies found a 
correlation between one dimension of insight and a facet of cognitive function such 
as spatial memory and performance IQ; one study found a correlation between a 
composite insight and cognitive function score; one study found no correlation 
between insight and cognitive function; and one study found a correlation between 
insight and cognitive function (i.e. immediate memory, working memory and 
sustained attention) for patients in remission, but not acutely psychotic patients.  
Results from these five studies suggest that impaired cognitive function might 
contribute towards poor insight, but that this relationship is complex.  In addition, the 
causal mechanism, if one exists, is not straightforward as only two of the five studies 
investigated the predictive power of cognitive function for insight.  Cognitive 
function was found to be predictive of insight in one study, but not found to be 
predictive of insight in a second study after adding symptomatology into the analysis 
which suggests that symptomatology is a stronger predictor of insight. 
The three longitudinal studies similarly suggest that cognitive function relates 
to insight, but that this relationship is not straightforward.  Two of the longitudinal 
studies utilised the same prospective cohort to investigate the relationship between 
insight and cognitive function.  However, the later study followed up participants 
over a greater number of years.  In regards to these two studies, the initial study 
found no association between insight and cognitive function at any time point, whilst 
34 
the second study found a correlation at one-year follow up.  Discrepancies in results 
might be due to differing psychological and pharmacological treatments that were 
provided to participants in the studies.  However, this was not explored in either of 
the studies.  These two studies also suggest that other factors such as social 
functioning, pathology and depressive symptoms might provide additional 
explanatory power of insight, as both of these longitudinal studies found some 
associations between these factors and insight at different time points.  The third 
longitudinal study used a different sample of participants and found that insight was 
related to cognitive function at baseline and two-year follow up. 
As mentioned in the previous section summary, the variation in results might 
be due to methodological differences that limit the extent to which the results can be 
applied and generalised.  Common limitations included use of different measures, 
lack of exploration of attrition rates and lack of control groups.  Strengths of some of 
the eight studies reviewed in this section include the use of a longitudinal design and 
recruiting a large sample of consecutively presenting patients with first-onset 
psychosis.  The next section of this review goes on to examine the relationship 
between insight and general cognitive function in patients with chronic 
schizophrenia, in order to investigate whether this relationship differs depending on 
duration of illness. 
 
The relationship between insight and general cognitive function in patients with 
chronic schizophrenia 
This second section includes 17 studies that examined the relationship 
between insight and general cognitive function in patients with chronic schizophrenia 
(Table 3). 
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Table 3 
The relationship between insight and general cognitive function in patients with chronic schizophrenia 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Stefanopoulou, 
Lafuente, Saez 
Fonseca and 
Huxley (2009) 
Design: Cross-sectional 
 
Sample: 36 schizophrenia; 
Age = 34.9 years (SD = 
9.8) 
 
BSI 
GAF 
ITAQ WAIS Insight is not associated with 
intellectual performance.   
Insight is associated with better global 
functioning, acknowledgement of 
psychotic symptoms and higher levels 
of anxiety. 
 
Kurtz and  
Tolman (2011) 
Design: Cross-sectional 
 
Sample: 72 schizophrenia; 
Age = 30.6 years (SD = 
10.8); Illness duration = 9.5 
years (SD = 9.7) 
 
BDI 
PANSS 
SWL 
PANSS CVLT 
FAS 
PCET 
WAIS 
Insight is associated with vocabulary.   
Deficits in vocabulary and digit span 
associated with poorer subjective 
quality of life. 
Cooke et al. 
(2007) 
Design: Cross-sectional 
 
Sample: 67 psychosis; Age 
= 38.1 years; Illness 
duration = 8.1 years 
 
BDI 
PANSS 
RSES 
IS 
PANSS 
Quick Test Self-reported insight (IS) is associated 
with IQ and self-esteem. Association 
between insight and IQ is curvilinear 
(quadratic). 
Clinician-rated insight (PANSS) is not 
associated with IQ, self-esteem or 
depression. 
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Table 3 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Donohoe, 
Donnell, Owens 
and O'Callaghan 
(2004) 
Design: Cross-sectional 
 
Sample: 38 schizophrenia; 
Age = 31.5 years (SD = 
8.7) 
 
CRI 
GAF 
MHLoC 
PANSS 
SAI MMSE 
NART 
Insight is associated with pre-morbid 
IQ, symptomatology and health 
attribution style. 
In regression analysis pre-morbid IQ is 
not predictive of insight. Symptom 
severity and health attribution are 
significant predictors. 
 
Chen et al. 
(2005) 
Design: Cross-sectional 
 
Sample: 31 schizophrenia; 
Age = 30.7 years (SD = 
8.5); Illness duration = 6.1 
years (SD = 7.1) 
 
GAF SAI 
KOS 
PCI 
WMS Clinician-rated insight is associated 
with verbal memory indices and global 
functioning (after controlling for age). 
Patients’ and caregivers’ insight is not 
associated with cognitive measures or 
global functioning. 
Ritsner and 
Blumenkrantz 
(2007) 
Design: Cross-sectional 
 
Sample: 85 paranoid 
schizophrenia; 8 residual, 7 
undifferentiated & 7 
disorganised; Age = 36.2 
years (SD = 10.2); Illness 
duration = 12.4 years (SD = 
8.6); Predominantly male 
 
CISS 
GSES 
PANSS 
RSES 
TPQ 
SUMD CANTAB In regression analysis neurocognitive 
factors (i.e. visual and movement 
skills, sustained attention and 
executive function) predict 20-41% of 
insight.  
Personality factors (i.e. temperament, 
autistic preoccupations, novelty 
seeking behaviour) predict 22-39% of 
insight. 
 
37 
Table 3 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Goodman, 
Knoll, Isakov 
and Silver 
(2005) 
Design: Cross-sectional 
 
Sample: 35 schizophrenia; 
Age = 38.0 years (SD = 
9.44); Illness duration = 
10.0 years (SD = 9.3); All 
male 
 
AIMS 
CDS 
SANS 
SAPS 
SASESE 
SUMD BVRT  
DOT-M 
Finger tapping test 
MMSE 
PNB (computerised) 
WAIS (digit span) 
Insight into symptoms, mental disorder 
and effects of treatment is associated 
with visual object learning, verbal 
working memory, ability to identify 
facial emotion and occurrence of 
violent events. 
 
Bora, Sehitoglu, 
Aslier, Atabay 
and 
Veznedaroglu 
(2007) 
Design: Cross-sectional 
 
Sample: 39 schizophrenia, 
13 undifferentiated & 6 
residual; Age = 32.6 years 
(SD = 8.3); Illness duration 
= 10.2 years (SD = 7.5); 
Predominantly male 
 
PANSS SUMD TOM 
WAIS 
WCST 
VF 
Insight into symptoms is associated 
with perseverative errors, WCST 
category score and deficits of first 
order and second order Theory of 
Mind (TOM) 
In regression analysis cognitive 
function is weakly predictive of 
insight, whilst TOM is most predictive 
of insight. 
 
Monteiro, Silva 
and Louza 
(2008) 
Design: Cross-sectional 
 
Sample: 30 paranoid 
schizophrenia & 10 
residual; Age = 34.0 years 
(SD = 7.2); Predominantly 
male 
 
PANSS SUMD CPT-II 
ROCF 
Stroop 
TMT 
WAIS (block design 
& vocabulary) 
WCST 
Insight is associated with executive 
function (WCST) and symptoms (i.e. 
negative factor and disorganization 
factor). 
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Table 3 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Lysaker, France, 
Hunter, and 
Davis (2005) 
Design: Cross-sectional 
 
Sample: 38 schizophrenia 
& 14 schizoaffective 
disorder; Age = 47.2 years 
(SD = 9.0); Predominantly 
male 
 
PANSS 
Quality of Life 
IPII 
NCRS 
SUMD 
HVLT 
WAIS (vocabulary) 
WCST 
Insight on SUMD is not associated to 
cognitive function.  
Insight on NCRS is associated to 
executive function. 
Lysaker, Tsai, 
Maulucci and 
Stanghellini 
(2008) 
Design: Cross-sectional 
 
Sample: 41 schizophrenia 
& 29 schizoaffective 
disorder; Age = 47.0 years 
(SD = 9.9); Predominantly 
male 
 
MCSDS 
PANSS 
Quality of Life 
IPII 
NCRS 
BLERT 
WAIS 
WCST (vocabulary, 
block design, 
arithmetic & digit 
symbol) 
WMS (logical 
memory) 
 
Full insight is associated with better 
executive functioning, social 
cognition, verbal memory and quality 
of life compared to superficial or 
limited insight. 
Lysaker et al. 
(2011) 
Design: Cross-sectional 
 
Sample: 41 schizophrenia 
& 24 schizoaffective 
disorder; Age = 46.3 years 
(SD = 8.9) 
 
MAS IPII 
SUMD 
CPT-II 
HVLT 
WAIS (digit symbol 
& vocabulary) 
WCST 
Insight is associated with verbal 
memory, visuomotor processing speed, 
executive function and sustained and 
selective attention. 
In regression analysis cognitive 
function was not predictive of insight 
after adding metacognition into 
analysis. 
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Table 3 (continued) 
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Gilleen, 
Greenwood 
and David 
(2011) 
Design: Cross-sectional 
 
Sample: 31 schizophrenia; 
Age = 38.2 years (SD = 
10.4); Illness duration = 
13.71 years (SD = 10.8) 
 
BPRS 
BDI 
BCIS 
SAI 
SUMD 
BADS 
Bells test 
MARS 
RMBT 
NART 
TMT 
WAIS 
Insight on SUMD is associated with 
TMT.   
Insight on SAI is associated with some 
measures of cognitive function. 
In regression analysis cognitive function 
is only a weak predictor of insight, 
whilst symptomatology is strong 
predictor. 
 
Donohoe, 
Corvin and 
Robertson 
(2005) 
Design: Between-groups 
 
Sample: 16 controls, 9 poor 
insight schizophrenia & 21 
good insight schizophrenia 
 
– Insight Scale NART 
Sustained attention 
Stroop 
TEA 
WAIS 
WMS 
Both patient groups (i.e. poor and good 
insight) performed less well on cognitive 
tasks than controls. 
The poor insight group performed below 
the good insight group on executive 
function and general cognitive function. 
In regression analysis verbal ability is 
predictive of insight. 
 
Varga, 
Magnusson, 
Flekkoy, 
David and 
Opjordsmoen 
(2007) 
Design: Between-groups 
 
Sample: 31 control group & 
32 schizophrenia 
 
BPRS 
CGI-S 
GAF 
MADRS 
SADS-C 
SCLFS 
SUMD AVLT 
Grooved pegboard 
Stroop 
TMT 
WAIS 
WCST 
The patient group had more cognitive 
deficits compared to controls. 
Insight is associated with attention, 
executive functioning, psychomotor 
speed, verbal learning and intelligence. 
Insight also associated with global 
functioning, emotions and illness 
severity. In regression analysis 
psychopathology and working memory 
were predictive of insight. 
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Table 3 (continued)  
Author(s) Design and Sample Clinical measure(s) Insight measure(s) Cognitive measure(s) Results 
Cuesta, Peralta, 
Zarzuela and 
Zandio (2006) 
Design: Longitudinal 
 
Sample: 37 schizophrenia, 
11 schizoaffective & 27 
affective disorder with 
psychotic symptoms; Age = 
33.7 years (SD = 9.0) 
 
CASH 
CGI-S 
AMDP 
ITAQ 
SUMD 
NAIP 
Stroop 
TMT 
VF 
WCST 
WAIS (Information) 
 
Insight is not associated with 
cognitive function at baseline or 
follow-up. 
Gharabawi et al. 
(2007) 
Design: Longitudinal 
retrospective cohort study 
 
Sample: 323 schizophrenia; 
Age = 41.0 years (SD = 
11.9) 
CGI-S 
LOF 
PANSS 
PSP 
PANSS Cogtest Insight at baseline is weakly 
associated to visual memory, 
attention/vigilance, reasoning and 
problem solving, declarative 
memory, and social cognition 
domains. 
At 1-year follow-up insight is 
associated with social cognition. 
 
ote. AIMS, Abnormal Involuntary Movements Scale; AMDP, Assessment and Documentation in Psychopathology; AVLT, Auditory Verbal Learning Test; BDI, Beck Depression Inventory; 
BCIS, Beck Cognitive Insight Scale; BLERT, Bell-Lysaker Emotional Recognition Task; BPRS, Brief Psychiatric Rating Scale; BSI, Brief Symptom Inventory; BVRT, Benton Visual Retention 
Test; CANTAB, Cambridge Neuropsychological Test Automated Battery; CASH, The Comprehensive Assessment Schedule History; CDS, Calgary Depression Scale; CPT, Continuous 
Performance Test; CRI, Coping Resources Inventory; CGI-S, Clinical Global Impression-Severity Scale; CISS, Coping Inventory for Stressful Situations; CVLT, California Verbal Learning 
Test; DOT-M, Dot Test-Modified; FAS, Controlled Oral Word Fluency; GAF, Global Assessment of Functioning Scale; GSES, General Self-Efficacy Scale; HVLT, Hopkins Verbal Memory 
Test; IPII, Indiana Psychiatric Illness Interview; ITAQ, Insight and Treatment Attitudes Questionnaire; KOS, Knowledge of Schizophrenia; LOF, Carpenter-Strauss Level of Functioning; 
MADRS, Montgomery-Asberg Depression Rating Scale; MARS, The Memory Awareness Rating Scale; MAS, Metacognition Assessment Scale; MCSDS, Marlowe–Crowne Social Desirability 
Scale; MHLoC, Multidimensional Health Locus of Control Questionnaire; MMSE, Mini-Mental State Examination; NART, National Adult Reading Test; NAIP, Neuropsychological 
Assessment Integrated Program; NCRS, Narrative Coherence Rating Scale; PANSS, Positive and Negative Syndrome Scale; PCET, Penn Conditional Exclusion Test; PCI, Perceived Cause of 
illness; PNB, Penn Neuropsychological Battery; PSP, Personal and Social Performance; RBMT, Rivermead Behavioural Memory Test; ROCF, Rey–Osterrieth Complex Figure test; RSES, 
Rosenberg Self-Esteem Scale; SADS-C, Schedule of Affective Disorders and Schizophrenia-change version; SAI, Schedule for the Assessment of Insight; SANS, Schedule for the Assessment 
of Negative Symptoms; SAPS, Schedule for the Assessment of Positive Symptoms; SASESE, Simpson-Angus Scale for Extrapyramidal Side Effects; SCLFS, Strauss-Carpenter Level of 
Functioning Scale; SWL; SUMD, Scale to Assess Unawareness of Mental Disorder; TEA, Test of Everyday Attention; TMT, Trail Making Test; TOM, Theory of Mind; TPQ, Tri-dimensional 
Personality Questionnaire; VF, Verbal Fluency; WAIS, Wechsler Adult Intelligence Scale; WCST, Wisconsin Card Sorting Test; WMS, Wechsler Memory Scale 
1. Dashes indicate data are not available
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Stefanopoulou, Lafuente, Fonseca and Huxley (2009) used the Insight and 
Treatment Attitudes Questionnaire (ITAQ) to investigate the relationship between 
insight and intellectual performance, global functioning and psychopathology in 36 
inpatients with chronic schizophrenia.  After corrections for multiple testing, results 
showed good insight was related to better global functioning, greater 
acknowledgement of psychotic symptoms and higher levels of anxiety.  However, no 
relationship was found between insight and intellectual performance, which was used 
to measure general cognitive functioning.  A lack of association between insight and 
cognitive function might have occurred due to the use of a uni-dimensional measure 
of insight and only one measure of cognitive function, as insight is a multi-
dimensional construct which might be associated with different aspects of cognitive 
function.  Measures were also administered as part of routine clinical evaluation by 
psychologists and therefore it is not known whether the measures of cognitive 
function and insight were administered within a close time frame or far apart, as 
fluctuations in psychopathology might have impacted on performance. 
Kurtz and Tolman (2011) also used a uni-dimensional measure of insight, 
embedded in the PANSS, to investigate the relationship between insight and multiple 
measures of cognitive function.  An association was found between insight and 
vocabulary as measured by the WAIS.  The findings also suggest that increased 
deficits in vocabulary and digit span were associated with poorer subjective quality 
of life.  A limitation of this study was that corrections for multiple testing were not 
carried out and therefore the risk of detecting a false positive result is increased.  In 
addition, similarly to Stefanopoulou et al. (2009), the use of a uni-dimensional 
measure of insight might have resulted in few associations between insight and 
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cognitive function and the authors note future studies should use a more 
comprehensive measurement of insight. 
Cooke et al. (2007) used a self-report insight scale (IS), as well as a clinician-
rated insight scale (PANSS) to explore the relationship between insight, IQ, self-
esteem and depression.  The clinician-rated insight measure was not associated with 
IQ, self-esteem or depression, whereas the self-reported insight measure was found 
to be associated with higher IQ and poorer self-esteem.  In addition, there was 
evidence for a curvilinear relationship between self-reported insight and IQ.  These 
findings suggest high cognitive ability is conducive, but not in itself sufficient, to 
having good insight.  The findings also suggest that some individuals may cope with 
psychosis in a way that promotes their own positive self-evaluation and thus 
manifests poor insight.  Selection bias might limit the ability to generalise the results, 
as participants included in the study were recruited from outpatients chosen for a 
randomised controlled trial of Cognitive Behavioural Therapy (CBT) for psychosis, 
and therefore the participants might be higher functioning or more motivated or 
engaged with services than is typical. 
Using the Schedule for Assessment of Insight (SAI), which is a semi-
structured clinician-administered multi-dimensional measure of insight, Donohoe, 
Donnell, Owens and O'Callaghan (2004) found an association between insight and 
pre-morbid intellectual functioning as measured by the National Adult Reading Test 
(NART) in 38 consecutively admitted inpatients.  However, pre-morbid intellectual 
functioning was not found to be predictive of insight when entered into a regression 
analysis, whereas, both symptom severity and having internal health attribution 
styles were found to be predictive of insight.  A limitation of the study was that no 
current measures of cognitive function were administered and therefore conclusions 
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can be drawn only about the relationship between insight and pre-morbid 
intelligence. 
Chen et al. (2005) also administered the SAI to investigate the relationship 
between insight, cognitive function (attention and memory) and global function in 31 
patients with schizophrenia.  The authors also administered an additional insight 
measure that assessed key caregivers’ perception about the disorder.  Clinician-rated 
insight, as measured by the SAI, was found to be associated with verbal memory and 
global functioning after controlling for age.  Insight, as measured by key caregivers, 
was not associated with cognitive function or global function.  In addition, there was 
no significant correlation between clinician-reported insight and key caregiver 
reported insight.  Together these findings led the authors to conclude that insight is 
related to cognitive function, but it is not influenced by psychosocial factors, such as 
caregiver perception.  A limitation of the study was the relatively small sample size 
and the variation in medication dosage between patients as some were drug naïve 
whilst others were taking medication. 
Administering a different multi-dimensional measure of insight, Ritsner and 
Blumenkrantz (2007) used the Scale to assess Unawareness of Mental Disorder 
(SUMD) to explore the relationship between the different dimensions of insight and 
cognitive function, personality traits and clinical characteristics in 107 clinically-
stable schizophrenic outpatients.  Across the three dimensions of insight measured by 
the SUMD, regression analysis showed that cognitive function (i.e. executive 
function, sustained attention, visual and motor skills) accounted for 20-41% of 
insight, whilst personality traits (i.e. temperament, autistic preoccupations and 
novelty seeking behaviour) accounted for 22-39% of insight.  These findings suggest 
insight is a multi-dimensional construct that is not only predicted by cognitive 
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function, but also personality traits.  The large sample size was a strength of the 
study.  However, the sample consisted of predominantly male participants who were 
clinically stable with symptoms in remission, which limits the ability to generalise 
the results. 
Goodman, Knoll, Isakov and Silver (2005) used the SUMD to explore the 
relationship between insight and demographic variables, clinical variables and 
cognitive function in a forensic inpatient unit with patients with a diagnosis of 
schizophrenia.  Analyses suggest that insight into having a mental disorder, the need 
for treatment and attributing symptoms to the mental disorder were significantly 
associated with visual object learning which indicates the possible involvement of 
frontotemperoparietal systems in insight.  Insight into the need for treatment was also 
associated with improved verbal working memory.  Insight into having a mental 
disorder was also associated with clinical variables that measured emotion 
processing and aggression control, where the authors found significantly higher 
scores on identification of facial emotions in patients with insight, and that poor 
insight was significantly associated with a higher occurrence of violence in the 
current hospitalisation.  This suggests that insight might share some underlying 
mechanisms that are associated with emotion processing.  A limitation of the study is 
that the authors do not appear to have used a two-tailed significance set at 5% and 
not performed corrections for multiple testing, which could have led to the possibility 
of Type I errors.  In addition, the study might have limited generalisability due to the 
client group recruited and therefore the study would have benefited from a 
comparison group to reduce this limitation. 
Utilising a Turkish version of the SUMD, Bora, Sehitoglu, Aslier, Atabay and 
Veznedaroglu (2007) investigated the relationship between insight and cognitive 
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function, symptomatology and Theory of Mind (TOM) in 58 Turkish outpatients 
with schizophrenia.  Results showed that 48% of participants had full insight into the 
current disorder, 50% had full insight into the effects of treatment and 43% had full 
insight into the social consequences of the disorder.  In addition, results showed 
participants had greater insight for current episodes of psychosis than past episodes 
of psychosis.  In regards to cognitive function, the misattribution of past positive 
symptoms of schizophrenia was found to be associated with perseveration on the 
Wisconsin Card Sorting Test (WCST).  Overall insight scores and unawareness of 
current positive symptoms were also associated with participant’s WCST category 
score.  An association was also found between poor insight and deficits of first order 
and second order TOM, which suggests that in order for an individual to be aware of 
their disorder, he/she needs to be able to imagine himself/herself from another 
person’s perspective.  A limitation of the study was the lack of correction for 
multiple statistical comparisons which could have inflated the chance of Type I 
errors. 
Monteiro, Silva and Louza (2008) administered a Portuguese version of the 
SUMD to investigate the relationship between insight, symptomatology and 
cognitive dysfunction in 40 outpatients with chronic, but stable, schizophrenia.  
Insight was associated with executive function as measured by the WCST.  However, 
as the neuropsychological battery administered had not been validated on the 
Brazilian population from which they recruited participants, the authors were only 
able to consider raw scores, which might have affected the analysis of results. 
Lysaker, France, Hunter and Davis (2005) also used the SUMD to assess the 
relationship between insight and cognitive functioning in 52 participants with 
schizophrenia.  In addition, they administered two novel measures that assess insight 
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by exploring patients’ illness narrative.  The Indiana Psychiatric Illness Interview 
(IPII) is a semi-structured interview which asks individuals: to provide details of 
their life story; if they think they have a mental illness; how they understand their 
mental illness; how their illness has affected their lives; how their illness ‘controls’ 
their life; and how they ‘control’ their illness.  The Narrative Coherence Rating Scale 
(NCRS) is an 18-point rating scale, which is then used to score the patient’s narrative 
coherence based on their IPII.  Three sub-scales on the NCRS measure insight by 
looking at whether details of the story are temporally connected in a logical 
sequential manner, how detailed the participants’ story are and whether their life 
stories are plausible.  Insight scores on the SUMD and NCRS were significantly 
correlated.  Insight, as measured by the SUMD, was not associated with cognitive 
function which was measured by vocabulary or executive function.  However, 
insight, as measured by the NCRS, was correlated with executive function.  A later 
study by Lysaker, Tsai, Maulucci and Stanghellini (2008) also found full awareness, 
as assessed by the NCRS, was associated with better flexibility in abstract thought 
(executive functioning), greater ability to detect difficult emotions (social cognition) 
and better verbal memory than superficial or limited awareness.  However, a 
limitation associated with both the Lysaker et al. (2005) and Lysaker et al. (2008) 
studies is that the IPII and NCRS measures of insight might be more prone to 
participants providing socially desirable responses to interviews as both studies rely 
on participant self-report.  A measure to gauge social desirability was administered in 
Lysaker et al.’s (2008) study at baseline, though no analyses of the data were 
presented.  Collecting socio-cultural background might have also been useful to 
explore social desirability. 
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Using the SUMD once more, Lysaker et al. (2011) found that in 65 patients 
with schizophrenia: poor insight into the mental disorder was associated with poor 
verbal memory; poor insight into the need for treatment was associated with poor 
verbal memory, visuomotor processing speed and executive function; and poor 
insight into the social consequences was associated with poor visuomotor processing 
speed, sustained attention and selective attention.  This study also investigated the 
relationship between insight and metacognition (i.e. the ability to think about your 
own thoughts and feelings and the thoughts and feelings of others), where multiple 
regression analysis showed that metacognition was predictive of insight after 
controlling for cognitive function.  Similarly to other studies, replication of this study 
with more diverse groups of participants would lead to greater generalisation of the 
findings, as this study recruited mainly male participants with clinically stable 
schizophrenia. 
Gilleen, Greenwood and David (2011) were interested in the relationship 
between insight, cognitive insight (i.e. awareness of cognitive impairments and 
functioning) and cognitive function.  Insight into having a mental disorder was 
associated with a measure of executive function that required speed of attention, 
sequencing and mental flexibility.  Insight into mental illness and labelling 
symptoms as part of a mental disorder was associated with executive function, 
current intellectual function and memory.  Insight into need for treatment was not 
associated with any measures of cognitive function, but was associated with 
cognitive insight.  Using regression analysis, cognitive insight was found to predict 
23% of the variance of insight into having a mental disorder.  A model consisting of 
psychopathology, self-reflection and executive function performance accounted for 
79.5% of the variance of insight into labelling symptoms as part of a mental disorder.  
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However, results should be interpreted with caution as the small sample size and lack 
of correction for multiple statistical testing might have led to weak or chance 
findings.  Replication of the study would provide further evidence for the findings.  
In addition, the authors recommend exploring the impact of variation in level of 
insight across groups, as discrepancies were observed where some patients were 
under aware whilst others were over aware. 
Using a between-groups design, Donohoe, Corvin and Robertson (2005) 
explored the relationship between insight and general cognitive measures in 30 
outpatients with chronic schizophrenia compared to controls.  Significant differences 
were observed between participants with poor insight, good insight and controls on 
all measures except reading and inhibition.  Good performance on measures of 
working memory, verbal ability and episodic memory were strongly associated to 
good insight.  In addition, logistic regression showed the WAIS vocabulary score 
explained 56% of variance in the poor insight group and 91% of variance in the good 
insight group.  These findings led the authors to conclude that insight might be 
related to verbal generalised deficits and therefore recommend that taking more time 
when communicating with patients with schizophrenia might compensate for 
cognitive impairments.  Limitations of this study include a relatively small sample 
size and lack of information on symptomatology which has been reported to impact 
on insight. 
Varga, Magnusson, Flekkoy, David and Opjordsmoen (2007) also used a 
between-groups design to investigate the relationship between insight and cognitive 
function.  Participants consisted of consecutively admitted outpatients diagnosed 
with schizophrenia or bipolar I disorder and matched controls.  All patients were in 
remission and/or well stabilised.  Both patient groups had significant 
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neuropsychological deficits compared to controls.  In the schizophrenia group, lack 
of insight was associated with poor global level of functioning, heightened emotions 
and increased severity of illness.  Degree of insight in the schizophrenia group was 
also associated with cognitive abilities including attention, executive functioning, 
psychomotor speed, verbal learning and intelligence.  A strength of the study was the 
inclusion of a comparison group of matched controls to see how diagnosis can 
impact performance on measures of cognitive function.  However, a limitation was 
not having another comparison group of patients with schizophrenia who were 
acutely unwell or who were not receiving medication. 
Cuesta, Peralta, Zarzuela and Zandio (2006) carried out a longitudinal study 
where they recruited 75 inpatients with a diagnosis of schizophrenia to investigate 
the relationship between insight and cognitive function, attention, memory and 
executive function.  Assessment took place at the point of discharge and then at 
follow-up which ranged between six months to two years post discharge once the 
patient was experiencing a phase of clinical stabilisation.  Nineteen patients (25%) 
dropped out of the study.  There were no differences between the patients who 
remained in the study versus those who dropped out, with the exception of 
educational background where patients who refused had a lower educational 
background than those who remained.  After controlling for multiple comparisons, 
no associations between insight and cognitive function were found at baseline or 
follow-up.  A strength of the study was that high inter-rater reliability was 
demonstrated within measures across authors and each researcher was blind to the 
measures of the other researchers.  A limitation was that participants were followed-
up from anywhere between six months to two years post discharge and the mean and 
standard deviation of this data is not available.  Although it was noted that this 
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variation in follow-up was due to waiting for patients to stabilise, it would be 
beneficial to know how this period varied between patients and what factors related 
to clinical stabilisation. 
Gharabawi et al. (2007), conducted post-hoc analysis on data collected from a 
one-year randomised controlled drug trial on 323 patients with schizophrenia.  
Measures of insight, symptomatology, cognitive function, general function and 
quality of life were administered at baseline and one-year follow-up.  At baseline, 
insight was highly correlated with measures of symptom severity, moderately 
correlated with general function and weakly associated to cognitive function 
(reasoning, problem solving, attention, visual memory and declarative memory).  At 
one-year follow-up, insight was associated with reduced symptomatology, longer 
adherence to anti-psychotic treatment and improved general functioning.  Insight was 
not related to cognitive function at one-year follow-up.  The longitudinal nature of 
this study allows the investigation of the relationship between insight and cognitive 
function over time.  However, a limitation of the study was the use of a uni-
dimensional measure of insight which could have reduced the likelihood of finding 
correlations between insight and cognitive function.  In addition, as data was 
gathered post-hoc, the authors note they were unaware of whether participants 
undergoing the study received other forms of treatment within the year such as 
psychosocial treatments, and therefore could not ascertain whether this impacted the 
findings of their study. 
 
Summary 
This section included 17 studies that investigated the relationship between 
insight and cognitive function in patients with chronic schizophrenia.  Thirteen 
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studies used a cross-sectional design, whilst two used a between-groups design and 
two used a longitudinal design. 
Twelve out of the 13 cross-sectional design studies found a correlation 
between at least one dimension of insight and cognitive function such as IQ, 
memory, attention or executive function.  The one study that did not find any 
association administered only one cognitive measure and a uni-dimensional measure 
of insight, whereas the other 12 studies used either: one cognitive measure and a 
multi-dimensional measure of insight; multiple cognitive measures and a uni-
dimensional measure of insight; or multiple cognitive measures and a multi-
dimensional measure of insight.  However, it is important to note that even though 
several of the twelve studies that found a relationship between insight and cognitive 
function used the same measures of insight, contradictory results were found 
between these studies.  For example, one study found a correlation between cognitive 
function and insight as measured by the PANSS, whereas another study did not. 
Both of the studies using a between-groups design found a significant 
difference between cognitive function in participants with a diagnosis of 
schizophrenia and controls, where participants with schizophrenia had significant 
neuropsychological deficits compared to controls.  The two studies also found an 
association between insight and cognitive function (i.e. working memory, verbal 
ability, memory, attention, intelligence and executive function). 
In regards to the two longitudinal studies that investigated the relationship 
between cognitive function and insight, the findings are less supportive of the 
premise that the two variables are associated.  One of the studies found no 
relationship between insight and cognitive function at baseline or follow-up.  The 
other study found a weak association between insight and cognitive function 
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(reasoning, problem solving, attention, visual memory and declarative memory) at 
baseline, but not at follow-up. 
In addition to exploring the relationship between insight and cognitive 
functioning, the majority of the studies investigated the relationship between insight 
and other capacities such as theory of mind, metacognition and cognitive insight.  
The impact of symptomatology and medication are also regularly examined.  The use 
of these supplementary measures is suggestive that insight cannot solely be 
determined by cognitive function and that other factors should also be analysed to 
explore their influence upon insight. 
When considering the relationship between insight and multiple variables in 
addition to cognitive function, 12 of the 17 studies carried out regression analysis to 
investigate the relative predictive powers of the multiple variables.  Four of the 
studies found that cognitive function was not predictive of insight.  Seven studies 
found that an aspect of cognitive function was predictive of insight, but that its 
predictive power was relatively weak.  The remaining study found that cognitive 
function was initially predictive of insight, but became a non-significant predictor 
once metacognition was added into the analysis. 
Variation between the studies findings is likely to be due to methodological 
differences, as mentioned in the two previous section summaries.  In addition, 
differing methods of statistical analysis and levels of stringency in regards to 
significance levels appear to impact results, as some studies found associations 
between insight and cognitive function prior to statistical corrections and no 
associations following such corrections. 
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Discussion 
Summary of findings 
The debate as to whether neuropsychological dysfunction can explain poor 
insight in patients with a diagnosis of schizophrenia has been ongoing for many 
years.  This is largely due to the impact of poor insight on prognosis (Giugiario et al., 
2011; Lysaker et al., 2002; Rossi et al., 2000).  The aim of this review was to 
contribute to the debate and summarise studies that investigated the relationship 
between neuropsychological dysfunction and insight that were published after recent 
reviews (Aleman et al., 2006; Shad et al., 2006).  The findings of this review largely 
corroborate earlier reviews and are indicative that although neuropsychological 
dysfunction is somewhat related to poor insight, that this relationship is by no means 
definitive, as it appears other factors also contribute towards the understanding of 
insight.  Teasing apart how and why specific cognitive domains are associated to or 
causally linked to insight is also difficult. 
In regards to the relationship between insight and executive function, the 
studies included in this review generally suggest that better executive functioning is 
associated with higher levels of insight (Jovanovski et al., 2007b; Lysaker et al., 
2006; Mysore et al., 2007; Raffard et al., 2009; Simon et al., 2006; Simon et al., 
2009).  However, this relationship is complex as different associations between 
insight and executive function were found and little explanation for why this is the 
case is available.  Differing associations could have arisen due to the multi-
dimensional nature of insight and executive function, as the results are indicative that 
some sub-dimensions of these constructs might relate to one another independently.  
In addition, differences in associations might be due to methodological limitations, as 
the studies included in the review administered various measures and recruited 
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different samples.  The findings are also suggestive that executive function alone is 
not sufficient to understand insight.  This is apparent when considering how the 
majority of studies gathered data on other variables such as symptomatology (Barrera 
et al., 2009; Simon et al., 2006; Simon et al., 2009) and medication (Raffard et al., 
2009; Simon et al., 2006), in addition to executive function in order to consider how 
these factors also relate to insight.  It is also notable that few studies performed 
regression analysis to examine whether executive function is predictive of insight 
and that of the studies that did perform regression analysis (Lysaker et al., 2006; 
Simon et al., 2006; Simon et al., 2009), executive function was found to be weakly 
predictive of insight, if at all. 
The relationship between insight and general cognitive function appears 
equally complex as the relationship between insight and executive function, as 
different domains of cognitive function were tested across the studies including: 
intelligence (Cooke et al., 2007; Morgan et al., 2010; Stefanopoulou et al., 2009); 
vocabulary (Kurtz & Tolman, 2011); memory (Chen et al., 2005; Goodman et al., 
2005; Lysaker et al., 2008; Lysaker et al., 2011); and attention (Ritsner & 
Blumenkrantz, 2007).  Together, theses studies would suggest that greater cognitive 
function is associated with a higher degree of insight, but that this relationship is 
more substantive in patients with chronic or stable schizophrenia, rather than in 
patients with acute or recent-onset schizophrenia (Subotnik et al., 2005).  However, 
few studies made direct comparisons between patients with different durations of 
illness and therefore the comparisons made across studies raise issues relating to the 
comparability of studies.  Also, few studies examined the relationship between 
insight and cognitive function over time.  The five studies that that did look at this 
trend (Cuesta et al., 2006; Gharabawi et al., 2007; McEvoy et al., 2006; Mintz et al., 
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2004; Saeedi et al., 2007) found mixed results where: insight was found to be related 
to cognitive function in patients with chronic schizophrenia at one-year follow-up in 
one study, but not another; and that insight was found to be related to cognitive 
function in patients with recent-onset schizophrenia at one-year follow-up in one 
study, at baseline and two-year follow-up in another study, and at no point in another 
study.   
In addition to exploring the relationship between cognitive function and 
insight, the majority of studies explored how other variables also related to insight.  
Other factors that related to insight included symptomatology (Mintz et al., 2004; 
Mutsatsa et al., 2006; Quee et al., 2011), medication (McEvoy et al., 2006), 
metacognition (Gilleen et al., 2011; Lysaker et al., 2011) and health attributions 
(Donohoe et al., 2004).  Moreover, few studies explored the predictive ability of 
cognitive function upon insight in patients with schizophrenia.  Of the studies that 
did employ regression analysis some found: cognitive function was predictive of 
insight (Cooke et al., 2007; Mutsatsa et al., 2006); cognitive function was a weak 
predictor of insight (Bora et al., 2007; Gilleen et al., 2011); cognitive function was 
not a significant predictor of insight when other variables were added to the analysis 
(Quee et al., 2011); and cognitive function was not predictive of insight at all (Cuesta 
et al., 2006; Donohoe et al., 2004; Gharabawi et al., 2007; Monteiro et al., 2008). 
Overall, it appears that executive function and cognitive function combined 
are only weakly associated with level of insight and the majority of studies explored 
how other factors such as TOM, metacognition, cognitive insight, symptomatology 
and medication are also associated with insight.  Determining causality from these 
studies is also problematic as not all the studies employed regression analysis to 
ascertain whether neuropsychological function was predictive of insight.  The studies 
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that carried out regression analysis tended to find that although neuropsychological 
function was associated with insight, that it was a weak predictor of insight and that 
it often became a non-significant predictor when adding other variables into the 
analysis.  It, therefore, seems likely based on these explorations that insight is a 
multi-dimensional construct that may be partially related to neuropsychological 
function, but that neuropsychological function needs to be analysed in conjunction 
with other variables to gain a holistic understanding of insight. 
 
Limitations 
It is evident from the studies included in this review that neuropsychological 
dysfunction cannot exclusively account for poor insight in patients with a diagnosis 
of schizophrenia.  Therefore, this review is limited in gaining a holistic view of the 
factors that contribute to level of insight, as this review focuses on studies that 
primarily investigated neuropsychological function and insight.  However, it is worth 
noting that many of the studies included in this review also examined other 
contributing factors such as symptomatology, metacognition and cognitive insight 
that were not focused on in this review.  This suggests researchers are aware of the 
need to expand the scope of investigations when examining insight. 
The studies included in this review also limit the conclusions that can be 
drawn, as there were commonly occurring methodological limitations across studies.  
Such limitations included: small samples of predominantly male participants; lack of 
comparison between patients of differing diagnoses, symptom severity, phase of 
illness, duration of illness, therapeutic history or control groups; lack of longitudinal 
studies; administering different measures of insight and neuropsychological function; 
and lack of statistical corrections when analysing the data. 
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Future directions 
Several recommendations can be made following this review of studies that 
investigated the relationship between insight and neuropsychological function.  
Firstly, to overcome the problems associated with comparing performance on 
different measures of insight, clinicians and researchers need to establish ‘gold 
standard’ measures in order to gain consistency of measurement across studies.  
Secondly, it is evident that there is a need for studies to recruit a more heterogeneous 
sample group, as the majority of studies had relatively homogenous samples of male 
participants.  A more heterogeneous sample would allow for greater generalisation to 
the wider population.  Thirdly, it would be valuable for studies to utilise more 
between-groups designs.  This is so that comparisons can be made between groups of 
participants such as exploring how differing diagnoses, symptom severity or duration 
of illness impacts the relationship between insight and neuropsychological function, 
because some studies found this relationship varied depending on some of these 
group differences.  Fourthly, it would be beneficial for future research to gather 
longitudinal data to enhance understanding around how insight changes over time, 
what factors mediate or maintain insight and the effect of treatment on insight.  
Finally, studies would benefit from continuing to explore whether sub-dimensions of 
neuropsychological predict sub-dimensions of insight and to expand the scope of 
research to investigate how other abilities relate to insight, as it is apparent that 
neuropsychological function cannot completely account for level of insight.  
Researchers that do this will need to ensure their studies are sufficiently powered by 
recruiting large samples of participants and taking steps to reduce errors associated 
with multiple statistical comparisons. 
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Clinical implications 
Clinical implications from this review can be considered, notwithstanding the 
limitations raised.  Evidence would suggest that poor insight in individuals with a 
diagnosis of schizophrenia can have a substantial impact on outcomes due to 
problems associated with poor insight such as lack of compliance with medication.  
However, patients with schizophrenia are not a homogeneous group and poor insight 
cannot be assumed as levels of insight can vary dramatically between patients with 
recent onset versus chronic schizophrenia, or between patients with acute versus 
stable symptoms.  These findings therefore highlight the importance of assessing 
insight in order to identify and treat patients who have poor insight and thus reduce 
the likelihood of poor outcomes. 
The findings would suggest that tests of neuropsychological function could 
be used as a means to potentially identify patients with poor insight, as poor 
neuropsychological function (i.e. executive function, memory and attention) is 
somewhat associated with poor insight.  However, the results suggest that 
neuropsychological dysfunction alone does not mean the patient will, without doubt, 
have poor insight.  Therefore, in addition to considering neuropsychological 
function, clinicians should also assess other likely contributory factors of poor 
insight such as theory of mind, symptom severity, medication, cognitive insight and 
metacognition which have also been found to be associated with insight. 
In addition to predicting insight by examining possible factors that could 
impair or promote insight, the results indicate that standardised measures of insight 
are available to clinicians.  Multi-dimensional measures of insight could be 
particularly beneficial in informing treatment planning, as identifying particular sub-
types of poor insight could be used to select aims and goals for an effective clinical 
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intervention.  For example: if a patient has poor insight into attributing symptoms of 
their illness to a mental disorder a clinician might attempt to help the patient re-label 
his or her symptoms as pathological; or if a patient has poor insight into the need for 
treatment a clinician might provide psychoeducation around the costs and benefits of 
medication. 
Overall, this review would suggest that understanding what factors can 
potentially impair insight in individuals with a diagnosis of schizophrenia is 
important.  This is because poor insight has implications upon prognosis and 
understanding insight in greater detail can help clinicians design interventions to 
improve insight and improve prognosis as a result. 
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Schizophrenia and fitness to plead in court and stand trial 
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Abstract 
Aim: In order for a defendant to receive a fair trial, he or she must be fit to plead 
and stand trial.  This study aimed to investigate whether having a diagnosis of 
schizophrenia impaired fitness to plead, as measured by a novel ecologically valid 
fitness to plead (FTP) test. 
Method: This study utilised a group comparison design to address whether 
participants with a diagnosis of schizophrenia (n = 26) would perform less well than 
healthy controls (n = 26) on the FTP test.  Standardised tests of intellectual ability, 
memory, executive function and symptom severity were also administered. 
Results: Participants with a diagnosis of schizophrenia performed less well on the 
FTP test than the healthy control group, despite having attended court more than the 
control group.  Regression analysis showed that diagnostic group predicted FTP test 
total score, but that education level was also a significant predictor.  In the group 
with a diagnosis of schizophrenia, verbal comprehension and auditory memory were 
associated with performance on the FTP test sub-scale that assessed understanding 
of plea options and court processes. 
Conclusion: Having a diagnosis of schizophrenia can impair fitness to plead and 
therefore attention needs to be given to this vulnerable group of defendants. 
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Introduction 
Fitness to plead and stand trial 
In England and Wales, a central determinant of a fair trial is whether a 
defendant is mentally capable of pleading and standing trial.  This right is upheld by 
the concept of fitness to plead which is determined on the basis of legal criteria 
established in mid-19
th
 century case law (Regina v. Pritchard, 1836), known as the 
Pritchard criteria.  The Pritchard criteria state that a defendant requires the ability to: 
1) plead; 2) understand evidence; 3) understand the court proceedings; 4) instruct a 
lawyer; and 5) know that a juror can be challenged.  Where these abilities are found 
to be lacking, a trial may not lawfully proceed (Regina v. Podola, 1960). 
At present, decisions about fitness to plead are based upon psychiatric 
opinion which is derived from clinical interview and consideration of any 
corroborating information about a defendants functioning.  Clinical psychologists 
may also assist if there are concerns over a defendant’s cognitive abilities (Rogers, 
Blackwood, Farnham, Pickup & Watts, 2008).  If a defendant is declared unfit to 
plead, the Criminal Procedure (Insanity and Unfitness to Plead) Act (1991) and the 
Domestic Violence, Crime and Victims Act (2004) state that the defendant can 
receive a hospital order (with or without a restriction order), a supervision and 
treatment order in the community or an absolute discharge. 
Formal findings of unfitness to plead are rare in England and Wales (Mackay, 
Mitchell & Howe, 2007).  This might be due to the subjective and often arbitrary 
process by which the Pritchard criteria are applied (Grubin, 1991).  Firstly, the 
criteria are not defined by legislation and therefore have been expanded to include 
other capabilities such as whether a defendant understands the nature of the charge, 
the details of the evidence and the meaning and consequences of entering a plea 
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(James, Duffield, Blizard & Hamilton, 2001).  Secondly, the frequency with which 
the criteria are applied varies (Kearns & Mackay, 2000).  A defendant’s ability to 
understand the course of the proceedings and ability to instruct a lawyer have been 
found to appear most frequently in psychiatric reports (Mackay, 2007; Mackay et al., 
2007).   Thirdly, the threshold for unfitness is considered to be too high and therefore 
only the most severely unwell defendants are determined as unfit to plead (Rogers et 
al., 2008).  Fourthly, fitness to plead might not be a unitary construct and, therefore, 
making definitive decisions might be difficult, as a defendant might be able to enter a 
plea, but not have the capacity to participate in the trial due to its demanding nature 
(Whittemore, Ogloff & Roesch, 1997). 
Difficulties associated with assessing fitness to plead causes concern.  
Inaccurate identification can delay legal proceedings and consume resources in both 
criminal justice and healthcare settings, as evidence suggests that a large majority of 
defendants for whom the court has ordered competency evaluations are actually fit to 
plead (Zapf & Viljoen, 2003).  Moreover, inaccurate identification might result in a 
defendant being declared fit to plead when they are, in fact, unfit to plead.  This 
might lead to an unfair trial and potentially incorrect disposal following trial.  For 
example, a defendant with a mental disorder might receive a prison sentence rather 
than a hospital order.  Furthermore, relying upon the fact that a defendant has been 
involved in previous trials does not guarantee that the individual understands court 
proceedings (McLeod, Philpin, Sweeting, Joyce & Evans, 2010). 
Due to concerns regarding the Pritchard criteria, the London Law 
Commission (2010) conducted a review of the existing law and recommended that 
the criteria be replaced with a new legal test which assesses whether a defendant has 
the decision making capacity for trial.  Attempts have also been made to standardise 
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the assessment of fitness to plead.  Nineteen standardised measures are currently 
available (Rogers et al., 2008).  However, the majority of these measures were 
developed in the United States and refer to the concept of adjudicative competency 
and not fitness to plead as assessed by the Pritchard criteria.  Akinkunmi (2002) 
adapted the MacArthur Competence Assessment Tool – Criminal Adjudication 
(MacCAT-CA: Hoge et al., 1999) to measure fitness to plead in England and Wales.  
Nevertheless, the measure is not much used in routine clinical practice.  Moreover, 
despite the availability of standardised measures in the United States, Borum and 
Grisso (1995) found that 80% of forensic psychiatrists rarely or never use 
standardised measures when assessing adjudicative competency. 
 
Schizophrenia and the criminal justice system 
A substantial proportion of defendants who are unfit to plead are reported to 
be experiencing psychotic symptoms (James et al., 2001).  Indeed, a meta-analysis of 
30 studies (Nicholson & Kugler, 1991) found that having a psychotic diagnosis and 
severe symptomatology were some of the strongest predictors of unfitness to plead.  
A more recent meta-analysis of 68 studies (Pirelli, Gottdiener & Zapf, 2011) also 
found that defendants diagnosed with a psychotic disorder were approximately eight 
times more likely to be found unfit to plead than defendants without a psychotic 
disorder.  Other studies have similarly found that having a psychotic disorder 
increases the risk of impairment (Cooper & Zapf, 2003; Rutledge, Kennedy, O'Neill 
& Kennedy, 2008; Viljoen, Roesch & Zapf, 2002; Viljoen, Zapf & Roesch, 2004). 
It is unsurprising that individuals with a psychotic disorder (e.g. 
schizophrenia) are likely to be declared unfit to plead as the disorder is associated 
with disordered thinking (Spitzer, 1997), reasoning biases (Garety et al., 2005), 
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cognitive impairments (O’Carroll, 2000; Sponheim et al., 2010) and social 
functioning deficits (Couture, Penn & Roberts, 2006), all of which could impact on 
whether a defendant is capable of participating in a trial (Crown Prosecution Service, 
2010). 
However, the way in which schizophrenia and its associated deficits impact 
upon fitness to plead has only been more recently investigated.  Hoge et al. (1997) 
reported that fitness to plead is associated with impaired cognitive function in 
participants with a diagnosis of schizophrenia.  Nestor, Daggett, Haycock and Price 
(1999) found that defendants declared as unfit to plead scored significantly lower on 
measures of IQ, attention, and verbal and episodic memory.  Viljoen et al. (2002) 
examined the relationship between fitness to plead and psychopathology in 
defendants in a forensic inpatient unit in Canada.  The authors found that among 
defendants with psychotic disorders, IQ was a significant predictor of understanding 
the nature and object of court proceedings.  More recently, Ryba and Zapf (2011) 
evaluated the influence of cognitive function and psychiatric symptoms on fitness to 
plead in forensic inpatients in the United States.  Their findings suggest that 
cognitive function (i.e. executive function, attention, memory and processing speed) 
accounted for more variance in the scores of three fitness to plead related abilities 
(i.e. understanding, reasoning and appreciation) than did psychiatric symptoms (i.e. 
psychoticism, hostility, depression and withdrawal).  However, there was an additive 
effect when these groups of variables were both considered. 
 
A novel standardised assessment of fitness to plead and stand trial  
As the Pritchard criteria and their haphazard application appeared to be 
failing to protect the best interests of mentally disordered or cognitively impaired 
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defendants, a research group consisting of psychiatrists, psychologists and legal 
practitioners was convened in 2006.  The research group aimed to develop an 
ecologically valid, structured, standardised measure of fitness to plead (FTP), which 
could be used by clinicians, in conjunction with psychiatric opinion, to improve the 
fairness of the administration of justice in these vulnerable groups and to inform 
practical improvements in the handling of their cases. 
The FTP test was developed in stages.  Firstly, the research group carried out 
a systematic review on the construct of fitness to plead (Rogers et al., 2008) and a 
qualitative study on the views of experienced Members of the Queen’s Counsel (QC) 
on the utility and validity of the Pritchard criteria (Rogers, Blackwood, Farnham, 
Pickup & Watts, 2009).  To ensure face validity and content validity of the FTP test, 
the QCs supported the research group in developing a script and filmed 
representation of a Crown Court proceeding typical of those in England and Wales, 
and questions pertinent to assessing fitness to plead.  The questions were informed 
by both the Pritchard criteria and consensus views elicited from the qualitative study.  
Thirdly, the FTP test was piloted on a sample of healthy control participants (n = 50) 
to assess the psychometric properties of the test.  Unreliable items that were endorsed 
by nearly everyone (ceiling effects) or by no one (floor effects) were discarded.  
Fourthly, the amended version of the FTP test was administered on a stratified 
sample of healthy control participants (n = 115) in order to develop performance 
norms.  This sample consisted of: approximately equal numbers of participants in 
three ability bands (i.e. scores below 89 = ‘below average,’ scores between 90-109 = 
‘average,’ and scores above 110 = ‘above average’) as determined by Wechsler 
Adult Intelligent Scale – Fourth Edition (WAIS-IV); approximately equal numbers 
of men and women in each of the three ability bands; and approximately equal 
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numbers of participants from four age groups in each of the three ability bands (i.e. 
aged 16-31, 32-47, 48-63 and 64-79).  This scale had a high level of internal 
consistency (Cronbach’s alpha = .807), which suggests the items are measuring an 
underlying construct. 
Following the development of the FTP test and administering the test on a 
stratified sample of healthy control participants, the research group aimed to examine 
how groups of mentally disordered and learning disabled participants performed on 
the FTP test.  This was to provide empirical data on a ‘minimum’ level of 
functioning required to satisfactorily meet the demands of engaging with a 
straightforward trial process.  Comparing differences between groups with known 
group differences would also provide discriminant validity (i.e. whether the test has 
the ability to distinguish between groups that are known to be different).  The FTP 
test had been piloted on participants with learning disability (n = 19), but not on any 
participants with metal disorders at the time of the present study.  The preliminary 
results suggest that participants with learning disability perform significantly worse 
on the FTP test than healthy control participants. 
In addition to comparing how different groups perform on the FTP test, the 
research group aimed to investigate the relationship between performance on the FTP 
test and domains of cognitive function and specific psychiatric symptoms.  At 
present, the assessment of fitness to plead relies upon psychiatric opinion as to how 
and to what extent these aspects of psychopathology might interfere with 
performance.  However, there is little empirical evidence to indicate precisely how 
cognitive function or psychiatric symptoms impacts upon actual court performance.  
Investigating these relationships would provide convergent validity (i.e. whether a 
particular measure of a construct is similar to another measure of a theoretically 
78 
similar construct), as the current research available suggests that impaired cognitive 
function (Ryba and Zapf, 2011) and increased psychiatric symptom severity 
(Nicholson & Kugler, 1991) is associated with unfitness to plead. 
 
The present study 
The present study formed part of a larger project by the research group 
mentioned earlier, which developed a novel standardised FTP test (Blackwood, Peay 
& Watts, 2012).  This study focused on: how having a diagnosis of schizophrenia 
would impact performance on the FTP test; and how performance on the FTP test 
related to cognitive function (i.e. intellectual ability, memory and executive function) 
and psychiatric symptoms.  This study also utilised data collected by the research 
group on healthy control participants (n = 115) to investigate whether the most recent 
version of the FTP test was a uni-dimensional or multi-dimensional test, and to 
investigate how participants with a diagnosis of schizophrenia performed on the FTP 
test compared to the healthy control group. 
 
Aims 
This study aimed to investigate the relationship between having a diagnosis 
of schizophrenia and performance on a novel FTP test.  The first research question 
was: is the FTP test a uni-dimensional or multi-dimensional test?  This was because 
it was not known whether the FTP test was measuring a unitary or multi-dimensional 
construct.  This also allowed for the investigation into the relationship between 
particular sub-dimensions of the FTP test and psychopathology.  The second research 
question was: would participants with a diagnosis of schizophrenia perform less well 
on the FTP test than healthy controls?  This was because psychopathology associated 
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with a diagnosis of schizophrenia is likely to compromise various abilities thought to 
underpin the task of pleading and standing trial.  The third research question was: did 
performance on the FTP test correlate with intellectual ability, memory, executive 
function and psychiatric symptoms?  This was because fitness to plead is likely to 
require: an understanding of complex language skills; verbal and non-verbal 
reasoning abilities; capacity to retain information in memory; and the ability to 
organise information and formulate a response.  In addition, symptoms of 
schizophrenia might interfere with and disrupt abilities that underpin fitness to plead. 
 
Method 
Design overview 
Factor analysis was used to address the first research question as to whether 
the FTP test is a uni-dimensional or multi-dimensional test.  A group comparison 
design was used to address the second research question as to whether participants 
with a diagnosis of schizophrenia would perform less well than healthy controls on 
the FTP test.  A ‘clinical group’ (i.e. participants with a diagnosis of schizophrenia) 
was compared to a ‘non-clinical group’ (i.e. healthy controls).  The dependent 
variable was the total score and sub-scale scores on the FTP test.  A correlational 
design was used to address the third research question regarding the relationship 
between fitness to plead, cognitive function and psychiatric symptoms.  The 
dependent variable was the total score and sub-scale scores on the FTP test.  The 
independent variables were the performance on measures of intellectual ability, 
memory, executive function and psychiatric symptoms. 
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Power analysis 
Power analysis was informed by a study by Akinkunmi (2002) which used 
the MacArthur Competence Assessment Tool – Fitness to Plead (MacCAT-FP) to 
compare fitness to plead in two groups of prisoners who had been charged with an 
offence and were awaiting trial.  A large effect size (d = 1.59) was observed in the 
study.  Power calculations were conducted using the “G*Power 3” computer 
programme (Faul, Erdfelder, Lang & Buchner, 2007) specifying two groups of equal 
sizes, a two-tailed test, a large effect size (d = 0.8), desired power at 80% and alpha 
at 5%.  The sample size required based on this calculation was 52 individuals with 26 
individuals per group. 
 
Ethical approval 
Ethical approval for the clinical sample (n = 26) was granted by the National 
Research Ethics Service (NRES) Committee London – Camberwell St Giles 
(Appendix 1).  Ethical approval for the healthy control group (n = 115) was obtained 
by the larger research group, and granted by the Psychiatry, Nursing and Midwifery 
Research Ethics Subcommittee at Kings College London (Appendix 2). 
 
Inclusion and exclusion criteria 
Participants in both diagnostic groups were eligible if they: 1) were aged 18-
65; 2) were fluent in English; and 3) could provide informed consent.  Participants in 
the clinical group were also required to have a diagnosis of schizophrenia or a related 
disorder based on the Diagnostic and Statistical Manual of Mental Disorders – 
Version 4 (DSM-IV: 1994) or the International Classification of Diseases – Version 
10 (ICD-10: 1992). 
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Participants in both diagnostic groups were excluded if they: 1) had severely 
impaired hearing or vision; 2) had a diagnosis of learning disability; and 3) had a 
history of neurological or psychiatric disease (i.e. major mental illness, head injury, 
epilepsy or substance abuse in the last month), not including a diagnosis of 
schizophrenia in the clinical group. 
 
Recruitment procedure 
Clinical group 
Participants in the clinical group were recruited via convenience sampling 
from a medium secure unit for mentally disordered offenders.  Participants that met 
the inclusion criteria were identified by the consultant psychiatrist and/or clinical 
psychologist on the ward.  Once identified, the researcher approached the potential 
participant to verbally describe the study, provide him with an information sheet 
(Appendix 3) and allow him to ask questions.  If the participant expressed an interest 
in the study, a date and time were arranged for a testing session approximately a 
week later.  This was done to provide the participant with adequate time to decide if 
he wanted to take part and to allow him to discuss the study with someone he knew 
well.  At the start of the testing session, the researcher reminded the participant about 
the study using the information sheet and clarified any questions.  Informed consent 
(Appendix 4) was also gathered at this time.  The testing session took approximately 
three hours.  Due to time restrictions in which testing could be carried out on the 
ward, the majority of participants underwent two 1½ hour testing sessions 
approximately a week apart.  Breaks within the 1½ hour testing sessions were also 
common due to participant request.  Participants were paid £25 for taking part. 
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Of the original pool of 57 participants who met the inclusion criteria, 12 were 
unable to be contacted (Figure 1).  Of the 45 participants who could be contacted, 27 
participants agreed to participate and 16 declined.  Of the 27 participants who agreed 
to take part, one participant dropped out of the study and had to be excluded from the 
analysis due to lack of a complete data set.  It is not known if the participants, who 
were unable to be contacted, declined to take part or dropped out of the study 
differed from the participants who completed the study because consent was not 
gained to access these participants’ demographic details. 
 
 159 patients 
in NLFS 
    
  
 
    
102 met 
exclusion 
criteria 
 57 met 
inclusion 
criteria 
   
   
 
   
 12 not 
contactable 
 45 
contactable 
  
    
 
  
  18 declined 
to participate 
 27 agreed to 
participate 
 
    
 
  
   1 dropped 
out of study 
 26 
completed 
study 
      
Figure 1. Flow diagram of the selection process for the clinical group 
 
on-clinical group 
Participants in the non-clinical group were selected from Blackwood et al.’s 
(2012) healthy control database (n = 115).  This sample was recruited by a researcher 
from the Institute of Psychiatry who was part of Blackwood et al.’s (2012) research 
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team.  Following self-selection via advertisement, the researcher telephoned the 
potential participant to discuss the study.  If the participant agreed to take part, a date 
and time for the testing session was arranged.  A different information sheet 
(Appendix 5) and consent form (Appendix 6) were given to participants in this 
group.  Participants were paid £7.50 an hour and reimbursed for travel. 
Of the 51 male participants in the database, 38 participants had complete data 
sets (Figure 2).  Twenty-six participants were selected from the 38 participants by 
removing the 12 participants with the highest education level.  This was because 
participants in the non-clinical group had significantly higher education levels than 
the clinical group. 
 
 115 controls in 
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64 female 
 
 51 male   
   
 
  
 13 incomplete 
data sets 
 38 complete 
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  12 highest 
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removed 
 26 control 
participants 
     
Figure 2. Flow diagram of the selection process for the non-clinical group 
 
Measures 
Demographic data and information about previous attendance at court 
Demographic data (i.e. age, ethnicity and education level) was collected via 
self-report.  In the clinical group, a participant’s previous court attendance was 
established by viewing court reports following informed consent.  In the non-clinical 
84 
group, a participant’s previous court attendance was collected via self-report and 
confirmed via the Police National Computer following informed consent. 
 
Fitness to plead measure 
Fitness to plead was assessed using Blackwood et al.’s (2012) novel measure.  
The fitness to plead (FTP) test is an ecologically valid fifteen minute scripted film 
depicting a Crown Court proceeding typical of those in England and Wales.  The 
film is recorded from the perspective of the defendant using actors in a hired 
courtroom.  The excerpt is based on realistic criminal trial material scripted through 
consultations with various experts including solicitors, criminal barristers and 
Queen’s Counsel.  The dialogue involves typical exchanges between a defendant and 
their defence counsel, followed by a witness examination from a prosecution 
barrister and then a cross-examination from a defence barrister.  The dialogue was 
designed to be sufficiently detailed in order to minimise ceiling and floor effects. 
Prior to beginning the test, participants were instructed to imagine that they 
were a defendant on trial charged with unlawful wounding and given other basic 
information about the test.  They were then asked a series of questions to check their 
understanding of the instructions, failing which, testing would be terminated.   
During the film participants viewed a series of excerpts relating to the charge 
‘against them,’ key prosecution evidence, a brief cross-examination and legal advice 
from their defence barrister.  At designated intervals, the film was stopped and 
participants were asked questions from a standardised interview schedule relating to 
what they had seen and understood.  Responses were written down verbatim during 
testing and scored immediately afterwards using a standardised scoring guide which 
allowed for a total score (0-79) and malingering score (0-4) to be generated.  A high 
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total score was indicative of better performance and a high malingering score was 
indicative of no evidence of malingering. 
 
Intellectual ability 
Intellectual ability was assessed using the Wechsler Adult Intelligence Scale 
– Fourth Edition (WAIS-IV: Wechsler, 2008).  The WAIS-IV is an internationally 
recognised assessment of general intellectual functioning for adults aged 16-90 years.  
The test comprises 12 subtests which are used to calculate a Full Scale Intelligence 
Quotient (FSIQ), as well as four indices: the Verbal Comprehension Index (VCI); the 
Perceptual Reasoning Index (PRI); the Working Memory Index (WMI); and the 
Processing Speed Index (PSI). 
 
Memory 
Memory was assessed using the Wechsler Memory Scale – Fourth Edition 
(WMS-IV: Wechsler, 2009).  The WMS-IV is an internationally recognised test of 
memory for adults aged 16-69 years.  Immediate and delayed auditory memory was 
assessed using the Logical Memory and Verbal Paired Associates sub-tests of the 
WAIS-IV which were used to generate the Auditory Memory Index (AMI). 
 
Executive functioning 
Executive function was assessed using the Hayling and Brixton tests (Burgess 
& Shallice, 1997).  The Hayling and Brixton tests assess executive function in adults 
aged 18-80 years.  The Hayling Sentence Completion Test (i.e. the Hayling) is 
divided into two sections that measure: 1) ability to initiate simple verbal responses 
quickly; and 2) ability to inhibit more obvious answers.  A total scaled score is 
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derived from the two sections by calculating speed of response and category errors.  
The Brixton Spatial Anticipation Test (i.e. the Brixton) is a visuospatial sequencing 
task with rule changes that measures mental flexibility, including the ability to follow 
and detect rules and shift responses accordingly.  A scaled score for the Brixton is 
derived from the total number of errors made.  Both the Hayling and Brixton tests 
scaled scores range from 1-10, where a score of 1 is considered impaired and a score 
of 10 is very superior.  A score of 6 would be considered in the average range. 
 
Psychiatric symptoms 
Psychiatric symptoms were assessed using the British Psychiatric Rating 
Scale (BPRS: Lukoff et al., 1986) which was completed by the participant’s 
consultant psychiatrist or clinical psychologist.  The BPRS is a 24-item instrument 
designed to assess a variety of psychiatric symptoms (e.g. anxiety, depression, 
grandiosity, hallucinations, unusual thought content and blunted affect) through 
observation and interview and has been shown to be a reliable tool for assessing a 
broad range of symptoms (Hedlund & Viewig, 1980).  Each item is rated on a seven-
point likert scale that ranges from ‘not present’ to ‘extremely severe.’  Ratings of two 
to three indicate a non-pathological intensity of a symptom, whereas ratings of four 
to seven indicate a pathological intensity of a symptom.  Total score ranges from 24 
to 168. 
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Results 
Participants 
Twenty-six male participants, recruited from a medium secure unit for 
mentally disordered offenders, were included in the clinical group (Table 1).  
Twenty-four of the participants had a diagnosis of paranoid schizophrenia and two 
had a diagnosis of schizoaffective disorder.  Age ranged between 22 and 58 years (M 
= 37.88, SD = 10.07).  Age of illness onset ranged between 16 to 36 years (M = 
22.38, SD = 5.97).  Illness duration ranged between 2 to 33 years (M = 15.50, SD = 
9.37).  Score on the British Psychiatric Rating Scale (BPRS: Lukoff, Liberman & 
Nuechterlein, 1986) ranged between 29 and 87 (M = 49.38, SD = 15.79) which 
indicated that participants were experiencing non-pathological to mild pathological 
intensity of symptoms.  All the participants were taking anti-psychotic medication. 
The non-clinical group included 26 male participants that were selected from 
Blackwood et al.’s (2012) participant database (n = 115) and matched in age to 
participants in the clinical group (Table 1).  Age ranged between 22 and 59 years (M 
= 37.77, SD = 12.69). 
There was no difference between the clinical group and non-clinical group in 
regards to age, t(50) = – .036, p = .971, d = .20.  There was a difference between the 
diagnostics group in regards to ethnicity (Fisher’s exact test = 11.91, p = .002), 
education level (Fisher’s exact test = 28.05, p < .001) and previous attendance at 
court (Fisher’s exact test = 19.17, p < .001). 
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Table 1 
Demographic information for the clinical (n = 26) and non-clinical group (n = 26) 
Measures Clinical group Non-clinical group 
Age mean (SD) 37.88 (10.07) 37.77 (12.69) 
Ethnicity n (%):     
White 9 (34.6) 18 (69.2) 
Black 16 (61.5) 4 (15.4) 
Asian 1 (3.8) 4 (15.4) 
Education level n (%):     
No qualifications 12 (46.2) 2 (7.7) 
GCSE 9 (34.6) 2 (7.7) 
A-Level 1 (3.8) 2 (7.7) 
Certificates 2 (7.7) 1 (3.8) 
Diploma 1 (3.8) 3 (11.5) 
Degree 1 (3.8) 16 (61.5) 
Previous attendance at court n (%):     
Never 0 (0.0) 11 (42.3) 
1-3 times 18 (69.2) 10 (38.5) 
4-6 times 7 (26.9) 2 (7.7) 
7+ times 1 (3.8) 1 (3.8) 
 
Data preparation 
The data were examined for normal distribution using the IBM Statistical 
Package for the Social Sciences – Version 19 (IBM SPSS Inc, 2010).  This consisted 
of visually inspecting histograms and testing for outliers, skewness and kurtosis by 
converting scores to z-scores.  No outliers were found and tests of kurtosis were not 
significant.  However, some of the variables were skewed.  In the clinical group, the 
non-normally distributed variables were: the WMS-IV Auditory Memory Index, 
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D(26) = .172, p = .047; the Hayling, D(26) = .203, p = .007; and the Brixton, D(26) = 
.258, p < .001).  In the non-clinical group, the non-normally distributed variables 
were: the Hayling, D(26) = .239, p = .001; and the Brixton, D(26) = .244, p < .001.  
Non-normally distributed variables were not transformed because no single 
transformation was able to consistently transform all the non-normal variables into 
normally distributed variables.  Variables that did not meet the assumptions of 
normality were analysed using non-parametric tests. 
Following tests for normal distribution, the Levene’s test for equality of 
variances was performed on the normally distributed variables.  All the Levene’s 
tests were not significant, which indicated that the spread of scores was roughly 
equal in the two groups.  The FTP test malingering score was not included in this 
study’s data analysis because ceiling effects were observed.  In addition, the utility of 
the score is yet to be determined. 
 
Comparison of intellectual ability, memory and executive function between the 
clinical and non-clinical group 
Independent samples t-test or Mann-Whitney tests were administered to 
compare performance on the WAIS-IV, WMS-IV, Hayling and Brixton between the 
diagnostic groups (Table 2).  The non-clinical group performed better than the 
clinical group on: the WAIS-IV Verbal Comprehension Index, t(51) = 3.84, p < .001, 
d = 1.06; the WAIS-IV Working Memory Index, t(51) = 4.836, p < .001, d = 1.34; 
the WAIS-IV Processing Speed Index, t(51) = 4.854, p < .001, d = 1.35; the WAIS-
IV Full Scale IQ, t(51) = 4.673, p < .001, d = 1.30; and the WMS-IV Auditory 
Memory Index, U = 229.00, p = .046, r = .28.  No difference in performance was 
observed between the diagnostic groups on: the WAIS-IV Perceptual Reasoning 
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Index, t(51) = .557, p = .580, d = .15; the Hayling, U = 346.00, p = .880, r = .02; and 
the Brixton, U = 268.00, p = .328, r = –.14. 
 
Table 2 
Comparative scores on the WAIS, WMS, Hayling and Brixton for the clinical (n = 26) and 
non-clinical group (n = 26) 
 Clinical group Non-clinical group   
Measures Mean (SD) Mean (SD) Statistic p 
WAIS:       
VCI 90.46 (14.05) 104.96 (13.17) t(51) = 3.84 >.001 
PRI 91.54 (11.78) 94.42 (23.63) t(51) = .557 .580 
WMI 86.00 (13.25) 106.19 (16.67) t(51) = 4.836 >.001 
PSI 79.88 (11.06) 94.35 (10.42) t(51) = 4.854 >.001 
FSIQ 85.46 (12.09) 101.58 (12.77) t(51) = 4.673 >.001 
WMS AMI 84.50 (19.14) 95.08 (12.71) U = 229.00 .046 
Hayling 5.12 (1.66) 5.08 (1.44) U = 346.00 .880 
Brixton 5.69 (1.87) 6.31 (1.95) U = 268.00 .328 
ote. AMI, Auditory Memory Index; FSIQ, Full Scale Intelligence Quotient; PRI, Perceptual Reasoning Index; 
PSI, Processing Speed Index; VCI, Verbal Comprehension Index; WAIS, Wechsler Adult Intelligence Scale – 
Fourth Edition; WMI, Working Memory Index; WMS, Wechsler Memory Scale – Fourth Edition 
 
Factor analysis of the fitness to plead test 
Factor analysis was conducted on Blackwood et al.’s (2012) FTP test, in 
order to ascertain whether the FTP test had a uni-dimensional scale in which all the 
questions were measuring the same underlying trait, or a multi-dimensional scale in 
which the questions were measuring related, but distinct underlying traits.  The 
healthy control sample (n = 115) was large enough (Kaiser-Meyer-Olkin = .677) and 
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there were sufficiently large enough correlations between questions for factor 
analysis (Bartlett’s test of sphericity, X
2
(406) = 982.75, p < .001). 
Factor analysis was performed using oblique rotation (direct oblimin), as 
there were strong grounds to expect that the factors might be related as all the items 
aimed to assess the construct of fitness to plead.  However, factor analysis using 
orthogonal rotation (varimax), where is it assumed that the factors are independent, 
was also conducted to investigate any potential differences between the analyses.  
There was no difference in the factors obtained from either analysis and therefore the 
results from the original oblique rotation were used. 
An initial analysis was run to obtain eigenvalues for each component in the 
data.  Ten components had eigenvalues over Kaiser’s criterion of 1.00 and in 
combination explained 65.40% of the variance.  The scree plot was slightly 
ambiguous and showed inflexions that would justify retaining three, four or five 
components from the 10, as components six to 10 did not explain a great deal of the 
variance.  Consequently, factor analyses with three, four and five components were 
run and compared.  Questions were assigned to a component if the factor loading was 
above .35.  If the question loaded onto more than one component, then the question 
was assigned to the component with the larger factor loading. 
Four components were retained in the analysis, based upon examination of 
the questions and discussion with the research team in regards to how the questions 
clustered onto the components in a conceptually meaningful way (Table 3). 
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Table 3 
Factor analysis results for the FTP test (n = 115) 
 
Factor 1: 
Understanding 
plea options and 
court processes 
Factor 2: 
Ability to follow 
proceedings and 
predict potential 
outcomes 
Factor 3: 
Understanding 
the consequences 
of being found 
guilty 
Factor 4: 
Understanding 
the consequences 
of being found 
not guilty 
Question 1 .673*  –.002 –.063 –.215 
Question 2 .659* –.120 –.025 –.044 
Question 3 .525* .241 .000 .171 
Question 4 .500* .062 .185 –.078 
Question 5 .453* –.070 .097 .021 
Question 6 .390* –.266 .285 –.183 
Question 7 .668* .188 .036 .224 
Question 8 .187 .534* –.225 .176 
Question 9 –.162 –.017 –.110 .522* 
Question 10 .629* .425* –.042 .121 
Question 11 .442* .261 .114 .243 
Question 12 .368* .004 .066 .182 
Question 13 .287 .015 .230 .016 
Question 14 .259 –.051 .234 –.049 
Question 15 .530* –.190 –.021 –.181 
Question 16 .453* .000 –.062 .193 
Question 17 .544* .032 .104 –.199 
Question 18 –.334 .551* .169 –.098 
Question 19 .487* .379* –.033 –.360* 
Question 20 –.366* .260 .626* –.084 
Question 21 .000 .056 .640* .024 
Question 22 –.067 .786* .091 –-.087 
Question 23 .149 .528* .174 –.134 
Question 24 –.043 –.011 .511* .289 
Question 25 .340 .014 .413* .032 
Question 26 .051 –.042 .006 .683* 
Question 27 .303 –.054 .397* .666* 
Question 28 .210 .006 .593* –.085 
Question 29 .297 –.041 .540* –.188 
ote. * = Factor loadings over .35 
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Factor 1 included 14 questions and appeared to represent an understanding of 
plea options and court processes, such as: understanding the charges; understanding 
the meaning of entering a plea; understanding the meaning and consequences of 
giving evidence; and understanding the roles of court personnel (i.e. judge, jury, 
defence barrister, prosecuting barrister and defendant). 
Factor 2 included four questions and appeared to represent an ability to 
follow proceedings and predict potential outcomes, such as: predicting how well a 
case is progressing; and the likelihood of being found guilty. 
Factor 3 included six questions and appeared to represent an understanding of 
the consequences of being found guilty, such as: the impact upon daily life; potential 
sentencing; and whether you are being treated fairly. 
Factor 4 included three questions and appeared to represent an understanding 
of the consequences of being found not guilty, such as: the impact upon daily life. 
In the clinical group, Factor 2 (D(26) = .208, p = .005) and Factor 4 (D(26) = 
.196, p = .012) were non-normally distributed.  In the non-clinical group, Factor 2 
(D(26) = .244, p < .001) and Factor 3 (D(26) = .179, p = .032) were non-normally 
distributed. 
 
Comparison of fitness to plead between the clinical and non-clinical group 
As predicted, total scores on the FTP test were higher for the non-clinical 
group (M = 52.38, SD = 4.96) than for the clinical group (M = 42.85, SD = 6.99), 
t(50) = 5.67, p < .001, d = 1.57 (Table 4). 
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Table 4 
FTP test scores in the clinical (n = 26) and non-clinical group (n = 26) 
 Clinical group Non-clinical group   
Measures Mean (SD) Mean (SD) Statistic p 
Total score: 42.85 (6.99) 52.38 (4.96) t(50) = 5.67 <.001 
Factor 1 1.10 (0.34) 1.59 (0.24) t(50) = 5.86 <.001 
Factor 2 2.69 (0.42) 2.79 (0.39) U = 292.50 .393 
Factor 3 1.67 (0.49) 1.96 (0.28) U = 189.50 .006 
Factor 4 1.64 (0.48) 1.68 (0.68) U = 332.50 .919 
 
In regards to the FTP test sub-scales obtained from factor analysis, the non-
clinical group scored higher than the clinical group on: Factor 1 (understanding plea 
options and court processes), t(50) = 5.86, p < .001, d = 1.63; and Factor 3 
(understanding the consequences of being found guilty), U = 189.50, p = .006, r = – 
0.38. 
Regression analysis was also carried out to see if diagnostic group was 
predictive of total score on the FTP test.  Diagnostic group explained a significant 
proportion of variance in the total score when entered into the regression model 
alone, R
2
 = .392, F(1, 50) = 32.184, p < .001.  However, the two diagnostic groups 
differed significantly in regards to several demographic variables (i.e. ethnicity, 
education level and previous attendance at court) and cognitive variables (i.e. 
intellectual ability and memory).  Therefore, ethnicity, education level, previous 
attendance at court, full scale IQ (as a representative of intellectual ability) and 
memory were entered into the regression analysis to see whether these variables were 
confounding variables.  The three demographic variables needed to be collapsed into 
two categories per group in order to be entered into the regression analysis: white vs. 
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non-white; low vs. high education level; and attended court vs. never attended court.  
When all the possible confounding variables were entered into the regression 
analysis, the new model predicted a greater proportion of the total score, R
2
 = .585, 
F(5, 46) = 10.371, p < .001.  Diagnostic group continued to explain a significant 
proportion of the total score, but less so than before, t(50) = –2.446, p = .018.  
Education level was also predictive of total score, t(50) = 2.083, p = .043.  Ethnicity 
(t(50) = –1.420, p = .163), previous court attendance (t(50) = 1.607, p = .115), full 
scale IQ (t(50) = .656, p = .515) and memory (t(50) = 1.907, p = .055) were not 
predictive of the total score on the FTP test. 
 
The relationship between fitness to plead and intellectual ability, memory, 
executive function and psychiatric symptoms in the clinical and non-clinical 
group 
Pearson correlation coefficients and Spearman’s correlation coefficients were 
conducted to examine whether the FTP test scores were associated with various 
variables in the clinical and non-clinical group.  Bonferroni correction (i.e. alpha 
divided by number of tests) was used to reduce the risk of type I errors and a more 
stringent alpha level was used to interpret results (p = .005). 
In the clinical group, associations were observed between: the FTP test total 
score and WMS-IV Auditory Memory Index, rs(26) = .552, p = .003; Factor 1 and 
WAIS Verbal Comprehension Index, r(26) = .598, p = .001; Factor 1 and WAIS Full 
Scale IQ, r(26) = .597, p = .001; Factor 1 and WMS-IV Auditory Memory Index, 
rs(26) = .665, p < .001; and Factor 1 and the Brixton, rs(26) = .561, p = .003 (Table 
5).  In the non-clinical group, no associations were observed between the FTP test 
scores and intellectual ability, memory or executive function (Table 6). 
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Table 5 
Correlations between FTP and the WAIS, WMS, Hayling, Brixton and BPRS for the clinical group (n = 26) 
 
FTP test total score 
Factor 1: 
Understanding plea 
options and court 
processes 
Factor 2: 
Ability to follow 
proceedings and predict 
potential outcomes 
Factor 3: 
Understanding the 
consequences of being 
found guilty 
Factor 4: 
Understanding the 
consequences of being 
found not guilty 
WAIS:      
VCI r = .490, p = .011 r = .598, p = .001* rs = .335, p = .094 r = .149, p = .467 rs = –.325, p = .105 
PRI r = .326, p = .104 r = .506, p = .008 rs = .045, p = .828 r = –.088, p = .670 rs = .017, p = .936 
WMI r = .381, p = .055 r = .423, p = .028 rs = .276, p = .172 r = .125, p = .542 rs = –.194, p = .342 
PSI r = .233, p = .253 r = .430, p = .028 rs = .208, p = .308 r = –.153, p = .457 rs = –.099, p = .631 
FSIQ r = .471, p = .015 r = .597, p = .001* rs = .310, p = .123 r = .071, p = .731 rs = –.253, p = .213 
WMS AMI rs = .552, p = .003* rs = .665, p < .001* rs = .348, p = .082 rs = .063, p = .759 rs = –.221, p = .277 
Hayling rs = –.218, p = .285 rs = .085, p = .679 rs = –.061, p = .767 rs = –.379, p = .056 rs = –.173, p = .399 
Brixton rs = .302, p = .133 rs = .561, p = .003* rs = .104, p = .614 rs = –.263, p = .194 rs = –.177, p = .288 
BPRS r = –.161, p = .433 r = –.084, p = .682 rs = –.074, p = .718 r = –.023, p = .910 rs = –.087, p = .672 
ote. AMI, Auditory Memory Index; BPRS, British Psychiatric Rating Scale; FSIQ, Full Scale Intelligence Quotient; PRI, Perceptual Reasoning Index; PSI, Processing Speed Index; VCI, 
Verbal Comprehension Index; WAIS, Wechsler Adult Intelligence Scale – Fourth Edition; WMI, Working Memory Index; WMS, Wechsler Memory Scale – Fourth Edition 
* = still significant following Bonferroni correction 
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Table 6 
Correlations between FTP and the WAIS, WMS, Hayling and Brixton for the non-clinical group (n = 26) 
 
FTP test total score 
Factor 1: 
Understanding plea 
options and court 
processes 
Factor 2: 
Ability to follow 
proceedings and predict 
potential outcomes 
Factor 3: 
Understanding the 
consequences of being 
found guilty 
Factor 4: 
Understanding the 
consequences of being 
found not guilty 
WAIS:      
VCI r = .385, p = .052 r = .504, p = .009 rs = –.040, p = .845 rs = .285, p = .158 r = –.217, p = .287 
PRI r = .300, p = .137 r = .466, p = .017 rs = –.032, p = .876 rs = .073, p = .725 r = –.115, p = .577 
WMI r = .516, p = .007 r = .503, p = .009 rs = .173, p = .399 rs = .164, p = .424 r = .115, p = .451 
PSI r = .177, p = .388 r = .203, p = .320 rs = .106, p = .606 rs = .077, p = .709 r = –.237, p = .243 
FSIQ r = .346, p = .068
 
r = .502, p = .009 rs = .044, p = .832 rs = .172, p = .402 r = –.223, p = .273 
WMS AMI r = .086, p = .675 r = .208, p = .307 rs = –.387, p = .051 rs = .202, p = .323 r = –.130 , p = .525 
Hayling rs = .406, p = .040 rs = .434, p = .027 rs = .209, p = .305 rs = .318, p = .113 rs = –.255, p = .217 
Brixton rs = .075, p = .716 rs = .098, p = .634 rs = –.048, p = .814 rs = .154, p =.452 rs = –.164, p = .424 
ote. AMI, Auditory Memory Index; FSIQ, Full Scale Intelligence Quotient; PRI, Perceptual Reasoning Index; PSI, Processing Speed Index; VCI, Verbal Comprehension Index; WAIS, 
Wechsler Adult Intelligence Scale – Fourth Edition; WMI, Working Memory Index; WMS, Wechsler Memory Scale – Fourth Edition  
* = still significant following Bonferroni correction 
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Discussion 
Summary of findings 
Is the FTP test a uni-dimensional or multi-dimensional test? 
Four factors emerged from the factor analysis on the healthy control group (n 
= 115).  This suggests that the FTP test is a multi-dimensional test that assesses 
distinct abilities, rather than a uni-dimensional test that assesses a unitary ability.  
Factor 1 appeared to represent an understanding of plea options and court processes.  
Factor 2 seemed to represent an ability to follow proceedings and predict potential 
outcomes. Factor 3 reflected an understanding of the consequences of being found 
guilty.  Factor 4 appeared to represent an understanding of the consequences of being 
found not guilty.  Participants with a diagnosis of schizophrenia performed less well 
on Factor 1 and Factor 3 compared to the healthy control group, but performed 
equally well on Factor 2 and Factor 4.  This finding lends further support to the 
assertion that the FTP test is a multi-dimensional test that measures distinct abilities 
and suggests that participants with a diagnosis of schizophrenia might be impaired in 
some domains of fitness to plead, but not others. 
 
Do participants with a diagnosis of schizophrenia perform less well on the FTP 
test than healthy controls? 
Participants with a diagnosis of schizophrenia performed less well on the FTP 
test overall compared to the healthy controls.  This finding supports the hypothesis 
that having a diagnosis of schizophrenia can impair fitness to plead.  Regression 
analysis further supported this finding, as diagnostic group was found to be 
predictive of total score on the FTP test before and after controlling for ethnicity, 
education level, previous court attendance, intellectual ability and memory. 
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However, it is important to note that when incorporating these variables into the 
regression model, education level was also predictive of performance on the total 
score of the FTP test.  This suggests that education level accounts for a proportion of 
the variance in the total score and is a possible confounding variable. 
 
Does performance on the FTP test correlate with intellectual ability, memory, 
executive function and psychiatric symptoms?  
When examining the relationship between performance on the FTP test and 
intellectual ability, there was an association between Factor 1 (understanding plea 
options and court processes) and the WAIS-IV Verbal Comprehension Index in the 
clinical group.  This would suggest that understanding plea options and court 
processes is related to acquired knowledge, memory for semantic information, 
general factual knowledge and abstract reasoning as measured by the Verbal 
Comprehension Index. An association was also found between Factor 1 
(understanding plea options and court processes) and the WAIS-IV Full Scale IQ in 
the clinical group.  Factor 1 was also associated with the WAIS-IV Perceptual 
Reasoning Index, WAIS-IV Working Memory Index and WAIS-IV Processing 
Speed Index prior to Bonferroni corrections for multiple statistical comparisons. 
Regarding the relationship between performance on the FTP test and 
memory, it was found that the FTP test total score and Factor 1 (understanding plea 
options and court processes) were associated with auditory memory (immediate and 
delayed) in the clinical group.  These associations might reflect the need for an 
individual to have the capacity to recall acquired knowledge, such as knowledge of 
court processes, in order to demonstrate an understanding of court proceedings. 
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Considering the relationship between performance on the FTP test and 
executive function, it was found that performance on Factor 1 (understanding plea 
options and court processes) was associated with performance on the Brixton test in 
the clinical group.  It is not clear why the Brixton test, which measures mental 
flexibility, would be associated with Factor 1 in particular.  Therefore, further 
investigation into the relationship between fitness to plead and alternative measures 
of executive function would be warranted in order to draw inferences from this 
association. 
In regards to the relationship between performance on the FTP test and 
psychiatric symptoms, no correlations were found between the FTP test total score 
and level of psychiatric symptoms in the clinical group, as measured by the BPRS. 
 
Comparison with past research 
The findings in this study are largely consistent with findings from past 
research.  This study suggests that the construct of fitness to plead is a multi-
dimensional construct, as four conceptually meaningful factors emerged from the 
factor analysis.  This finding is in accordance with past research that also suggests 
that fitness to plead is a multi-dimensional construct, whereby an individual might 
possess ability in one area, but not another (Whittemore, Ogloff & Roesch, 1997). 
The finding that participants with a diagnosis of schizophrenia performed less 
well on the total score of the FTP test compared to the healthy controls is also 
consistent with previous studies which found that having a psychotic diagnosis can 
impact upon fitness to plead (Cooper & Zapf, 2003; James et al., 2001; Rutledge et 
al., 2008; Viljoen et al., 2004).  The regression analysis also showed that previous 
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attendance at court does not predict fitness to plead, which has been found in past 
studies (McLeod et al., 2010). 
Considering the relationship between fitness to plead and cognitive function, 
similarly to Viljoen et al. (2002), this study found that there was a relationship 
between some factors of the FTP test and some sub-scales of intelligence.  In 
addition, this study found that total score on the FTP test was associated with 
auditory memory in the clinical group, which is in line with Nestor et al. (1999) who 
also found that fitness to plead related to verbal memory. 
It was surprising that no association was found between psychiatric 
symptoms and performance on the FTP test, as previous studies suggest that 
symptoms are some of the strongest predictors of fitness to plead (Nicholson & 
Kugler, 1991; Pirelli et al., 2011).  However, this study’s clinical sample consisted of 
participants that were experiencing non-pathological to mild pathological intensity of 
symptoms on the British Psychiatric Rating Scales (BPRS), whereas Nicholson and 
Kugler (1991) noted that severe symptomatology is associated with impaired fitness 
to plead.  Therefore, an association between psychiatric symptoms and performance 
on the FTP test might have occurred if participants with more acute symptoms had 
been recruited. 
 
Limitations 
This study had various limitations which affect the ability to draw firm 
conclusions and generalise the study’s findings. 
 
Limitations with the clinical group 
The ability to generalise this study’s findings, beyond the homogenous clinical 
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group that was recruited, is limited in that: the majority of participants had a 
diagnosis of paranoid schizophrenia; most had mild psychiatric symptoms; the 
majority had chronic schizophrenia; all participants had previously attended court; 
and all the participants were male.  Consequently, it is not known how: participants 
with different sub-types of schizophrenia (e.g. disorganised sub-type or residual sub-
type); participants with acute symptoms; participants with recent-onset schizophrenia; 
participants who have not attended court; or female participants with schizophrenia 
would have performed on the FTP test compared to the present clinical sample. 
Selection biases were likely to have occurred due to the where the 
participants were recruited from and the recruitment procedure.  In terms of the 
recruitment location, all the participants were recruited from a medium secure 
forensic unit in which many of the patients had long histories of mental illness, but 
whose acute symptoms were largely in remission due to assertive pharmacological 
intervention.  In addition, there was only one female ward out of eight and, therefore, 
sufficient numbers of female participants, who met the inclusion criteria, could not 
be recruited.  In terms of the recruitment procedure, a selection bias towards 
recruiting participants with mild symptoms might have occurred because: it was only 
deemed appropriate to approach a patient if his mental state was stable enough to 
engage with the testing procedure; and patients with more severe symptoms, 
particularly negative symptoms of schizophrenia, appeared poorly motivated and 
were more likely to decline to participate. 
 
Limitations with the comparability of the clinical and non-clinical group 
There were significant differences between the clinical group and non-clinical 
group in this study in terms of ethnicity, education level, previous court attendance, 
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intellectual ability and memory.  This impacts the ability to draw firm conclusions 
about whether having a diagnosis of schizophrenia alone impacts fitness to plead, as 
although diagnostic group was found to be predictive of fitness to plead after 
attempts to control for these variables, it was clear that education level was also a 
significant predictor of performance on the FTP test. 
The discrepancy between the two groups ethnicity might have occurred due 
to inherent biases within the forensic system, where a disproportionate number of 
inpatients come from Black ethnic origins.  Regarding intellectual ability, the 
discrepancy between the groups might have occurred due to the participants in the 
clinical group having significantly fewer years in education than the non-clinical 
group, as poor engagement with the educational system can impact aspects of 
intelligence, such as acquired knowledge and crystallised knowledge. 
 
Limitations with the testing procedure 
Limitations of the study were also associated with the administration of the 
various measures.  Firstly, some of the participants were observed to become 
uninterested or fatigued during the testing session despite taking breaks throughout.  
Secondly, order effects might have affected performance on the measures, as the 
measures were not administered in a standardised order due to participant’s taking 
breaks at differing times during the testing session and because of ward procedures 
such as smoking break taking place during the testing session.  Thirdly, although the 
BPRS has been shown to be a reliable tool for assessing symptoms (Hedlund & 
Viewig, 1980) the inter-rater reliability in this study is not known. 
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Limitations associated with the FTP test 
There were several limitations associated with the FTP test used in this study.  
In terms of reliability, the FTP test had high internal consistency, but the inter-rater 
and test-retest reliability were not known as they were still in the process of being 
established by the research group.  In relation to validity, the FTP test had face and 
content validity, but the construct validity was yet to be determined.  This was 
largely due to the continuing debate over the construct of fitness to plead making it 
difficult to operationalise the construct into observable and measurable behaviours 
(Law Commission, 2010).  It was also not known whether the FTP test has 
concurrent validity and if it correlates with psychiatric opinion on fitness to plead or 
other standardised measures. 
Factor analysis on the FTP test was carried out in this study to determine if 
the test was uni-dimensional or multi-dimensional.  Even though four factors 
emerged, which suggested that the FTP test was multi-dimensional, differences in the 
number of items that clustered onto each factor might have limited the results of this 
study’s findings.  This was because Factor 2, 3 and 4 contained fewer items than 
Factor 1 and these factors had larger standard deviations.  This might have reduced 
the chances of detecting small differences in performance on these factors, as the 
sample size in this study was relatively small. 
Another limitation of the FTP test used in this study was that cut-off scores, 
in which a participant would be declared unfit to plead, were yet to be established.  
Therefore, even though the participants with a diagnosis of schizophrenia performed 
statistically less well on the FTP test than the healthy control group, it is not known 
whether this difference is clinically significant or meaningful. 
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Future directions 
In order to reduce some of the limitations of the present study, several 
recommendations can be made.  A larger participant sample should be recruited to 
increase the chances of detecting effects, as some of the significant findings became 
non-significant when controlling for multiple comparisons.  It would also be 
beneficial to recruit participants with other sub-types of schizophrenia, more acute 
symptoms and different illness durations in order to investigate how these variations 
in presentations might impact performance on the FTP test.  This is because studies 
have shown that unfitness to plead is associated with acute symptoms (Nicholson and 
Kugler, 1991) and also particular symptoms of schizophrenia, such as disorganised 
and delusional thinking (James et al., 2001).  However, it is worth noting that 
recruiting acutely psychotic or severely disturbed patients is difficult and careful 
consideration would need to be taken to devise a strategy to engage severely unwell 
participants.  Recruiting participants with a diagnosis of schizophrenia who have not 
attended court in the past would also be important.  Greater care should also be taken 
to match comparison groups, as it would be important for future studies to minimise 
the effects of potential confounding variables.  It would also be interesting for future 
studies to gain psychiatric opinion as to whether the participant is fit to plead or to 
administer another standardised measure to assess whether the FTP test has 
concurrent validity. 
 
Clinical implications 
Despite this study’s limitations, clinical implications can be drawn.  Firstly, 
this is the first study to have administered the FTP test on participants with a 
diagnosis of schizophrenia.  Therefore, its findings provide valuable information on 
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how this group of participants responds to the measure and provides a baseline level 
of performance on the FTP test.  Moreover, the results contribute to the evaluation of 
the psychometric properties of the FTP test, in that the results suggest the FTP test 
has discriminant validity, as the measure was capable of distinguishing performance 
between participants with a diagnosis of schizophrenia compared to healthy controls. 
Secondly, similarly to other studies, this study highlights the importance of 
increasing legal professionals’ awareness of the potential impact of mental disorders 
on fitness to plead.  This is because participants with schizophrenia performed less 
well on the FTP test than healthy controls.  Furthermore, this study emphasises that 
even mild symptoms of schizophrenia can impair fitness to plead.  This finding is 
particularly important as, at present, the threshold for unfitness is extremely high and 
concerns regarding fitness to plead are only raised in cases where a defendant is 
extremely unwell.  Therefore, these findings suggest that the judgment process 
should be more systematic and that legal professionals should raise concerns to the 
court regarding fitness to plead if a defendant has any history of a mental disorder, 
rather than only raising concerns when a defendant is severely unwell. 
Thirdly, the results suggest that clinicians should conduct a proper evaluation 
of a defendant’s cognitive functioning, particularly verbal comprehension and 
auditory memory, as part of a thorough assessment of fitness to plead.  This is 
because these particular cognitive deficits were associated with impaired fitness to 
plead.  Information on a defendant’s cognitive function could also inform decision 
making in regards to whether the trial should: continue as normal; continue as long 
as special measures or modifications to the trial process are put in place to support 
the defendant; or be delayed until the defendant is more fully treated.  Special 
measures could include taking greater time in explaining court procedures, 
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simplifying language, having a shortened hearing, having regular breaks, providing 
memory aids, or seating defendants next to an advocate. 
Fourthly, the results indicate that legal professionals need to ascertain a 
defendant’s fitness to plead on a case by case basis, and not assume a defendant is fit 
to plead based upon previous attendance at court.  This is because, despite all the 
participants with a diagnosis of schizophrenia having attended court in the past, they 
still performed less well on the FTP test than the healthy control group (42% of 
whom had never been to court). 
Overall, the results would suggest that careful consideration needs to go into 
the assessment of fitness to plead, and that the identification and screening of 
defendants with a diagnosis of schizophrenia is imperative.  This is to ensure the 
administration of justice, whereby these vulnerable individuals receive a fair trial in 
which they are supported and able to meaningfully participate in their defence. 
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Part 3: Critical Appraisal 
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This critical appraisal considers two main areas of concern that arose during 
the course of this study which merit further reflection.  The first section discusses the 
fact that fitness to plead is a poorly defined and controversial construct and that this 
in turn impacts upon its assessment and the development of standardised measures.  
The section concludes with a discussion on the development of the fitness to plead 
(FTP) test used in this study and the problems associated with administering a test 
that is yet to undergo rigorous tests of reliability and validity.  The second section 
considers the heterogeneous nature of schizophrenia and the challenges associated 
with conducting and generalising research in this clinical population.  The section 
goes on to discuss how sub-types of schizophrenia and different levels of symptom 
severity and illness duration might impair fitness to plead more or less.  The section 
concludes with a discussion on whether the FTP test is appropriate for assessing 
fitness to plead across the spectrum of schizophrenia or if it needs to be adapted in 
view of the heterogeneous nature of the disorder. 
 
The construct of fitness to plead and the implications upon its assessment 
The construct of fitness to plead and its limitations 
In England and Wales, fitness to plead is viewed as unitary construct that is 
assessed using the Pritchard criteria (Regina v. Pritchard, 1836).  The criteria state 
that a defendant must be able to: plead to the indictment; understand the evidence; 
understand the court proceedings; instruct a lawyer; and challenge a juror.  If the 
defendant does not have capacity in relation to any one of these five areas, then the 
defendant should be considered unfit to plead. 
However, evidence would suggest that fitness to plead might not be a unitary 
construct as a defendant might be able to enter a plea, but not have sufficient 
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capacity to participate in the trial due to its demanding nature (Whittemore, Ogloff & 
Roesch, 1997).  In addition, a review by the Law Commission (2010) argues that the 
Pritchard criteria are not adequate in assessing fitness to plead.  Other abilities that 
are deemed important, but that are not incorporated in the criteria include whether a 
defendant understands: the role of court personnel; the nature of the charges; the 
meaning and consequences of entering a plea; the implications of evidence and 
cross-examination; and the implications of the court’s sentence (Mackay, Mitchell & 
Howe, 2007). 
 
The assessment of fitness to plead and its limitations 
Psychiatric opinion is considered gold standard if a mental disorder is 
suspected of impairing a defendant’s ability to plead and stand trial (Akinkunmi, 
2002).  For example, an acutely psychotic defendant with thought disorder might 
lack the ability to understand the evidence or follow court proceedings due to 
symptoms interfering with reasoning and comprehension. 
Nevertheless, there are concerns regarding the reliability of clinical judgment.  
Mackay et al. (2007) found that only 58 out of 641 pre-trial psychiatric reports 
addressed all five Pritchard criteria when commenting on fitness to plead and that 89 
of such reports determined fitness to plead based simply on mental health diagnosis.  
In addition, the frequency of which the criteria are applied varies (Mackay, 2007).  It 
is not known why some criteria, in particular, are given more weight than others, but 
this raises questions as to what abilities are considered essential to be fit to plead and 
at what point does an individual become unfit.  The current threshold at which a 
defendant is declared unfit is considered too high as the formal findings of unfitness 
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are extremely rare, despite few defendants being able to understand all five criteria 
(Rogers, Blackwood, Farnham, Pickup & Watts, 2008). 
 
The standardised measurement of fitness to plead and its limitations 
Due to concerns regarding the Pritchard criteria, the Law Commission (2010) 
recommended that standardised measures should be used in conjunction with 
psychiatric opinion.  Attempts have been made to standardise the assessment of 
fitness to plead and 19 measures are currently available (Rogers et al., 2008).  
Standardised methods include the use of checklists, sentence-completion tasks, self-
report questionnaires and structured interview. 
Notwithstanding the potential value of standardised measures, there are 
limitations that need to be considered.  Firstly, the majority of measures are based on 
case law in the United States and Canada.  Therefore, the utility of using such 
measures in England and Wales is questionable as differences in the construct of 
fitness to plead causes concerns regarding the construct validity of measures.  
Secondly, the availability of scoring criteria varies and can lead to ambiguity and 
subjective analysis of the results.  Moreover, developing a standardised measure is a 
complex process.  Grisso and Borum (2003) advised that a measure should: 1) be 
guided by legal theory; 2) capture all relevant legal constructs; 3) have quantitative 
measures that reflect performance; and 4) have standardised administration to 
promote reliability.  However, as discussed earlier, the construct of fitness to plead is 
controversial and therefore impacts the ability to capture relevant constructs and 
operationalise fitness to plead in terms of observable and measurable behaviours. 
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The novel measure of fitness to plead used in the present study and its limitations 
Blackwood, Peay and Watts (2012) developed a novel standardised measure 
of fitness to plead due to the problems associated with its current assessment.  The 
fitness to plead (FTP) test was not designed to rigidly adhere to the Pritchard criteria 
in view of likely modifications to the test.  Rather, it was based upon a qualitative 
study on the opinions of senior criminal barristers on the construct of fitness to plead 
and the procedural difficulties associated with its assessment (Rogers, Blackwood, 
Farnham, Pickup & Watts, 2009).  Therefore, the FTP test aimed to assess: 1) the 
ability to plead (e.g. the ability to understand the allegation and the meaning and 
consequences of entering a plea); 2) and the ability to participate in a trial (e.g. the 
ability to provide coherent instructions to counsel, follow the details of evidence and 
have the belief that the Court will seek to fairly establish facts). 
A limitation of the FTP test used in this study was that it had not yet 
undergone tests of reliability and validity as earlier versions had.  Nevertheless, 
inferences about reliability and validity can be drawn from this study.  Firstly, the 
FTP test appeared to have face validity as the four factors derived from factor 
analysis did correspond broadly to Rogers et al.’s (2009) reformulation, whereby: 
Factor 1 (understanding plea options and court processes), Factor 3 (understanding 
the consequences of being found guilty) and Factor 4 (understanding the 
consequences of being found not guilty) appeared to correspond with Rogers et al.’s 
(2009) ability to plead; and Factor 2 (ability to follow proceedings and predict 
potential outcomes) appeared to correspond with Roger et al.’s (2009) ability to 
participate in a trial.  Secondly, the FTP test appeared to have internal consistency, a 
type of reliability, as the questions clustered onto four factors in a conceptually 
meaningful way.  Thirdly, the FTP test appeared to have convergent validity as 
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performance on some sub-scales of the FTP test were associated to verbal 
comprehension and auditory memory, which have been found in previous studies 
(Ryba & Zapf, 2011; Viljoen, Roesch & Zapf, 2002).  However, further research 
needs to be conducted in order to confidently assert that the FTP test has convergent 
validity.  In addition, other tests of reliability (e.g. inter-rater and test-retest 
reliability) and validity (e.g. content and concurrent validity) need to be investigated 
to fully establish the psychometric properties of the FTP test. 
 
The challenges of assessing fitness to plead in individuals with schizophrenia 
The nature of schizophrenia and its implications on research 
Schizophrenia is characterised by positive and negative symptoms (National 
Institute for Health and Clinical Excellence: NICE, 2009).  Positive symptoms 
include hallucinations, delusions and behavioural disturbances.  Negative symptoms 
include social withdrawal, apathy, memory problems, concentration problems and 
disturbed communication and affect.  In order to be diagnosed with schizophrenia, 
the Diagnostic and Statistical Manual for Mental Disorder – Fourth Edition (DSM-
IV: American Psychiatric Association, 1994) states that an individual must 
experience a certain number of these symptoms for at least six-months and where 
such symptoms cause deterioration in social or occupational function. 
However, the prevalence of these symptoms and the severity in which they 
are experienced varies considerably, whereby each individual will have a unique 
combination of symptoms and experiences (NICE, 2009).  This disparity in 
presentation is further highlighted by the fact that the DSM-IV contains five sub-
classifications of schizophrenia that are characterised by different symptomatology 
including: 1) the paranoid sub-type (i.e. delusions or auditory hallucinations are 
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present, but thought disorder, flat affect and disorganised behaviour are not); 2) the 
disorganised sub-type (i.e. thought disorder and flat affect are present together); 3) 
the catatonic sub-type (i.e. the patient might be almost immobile or exhibit agitated 
purposeless movement); 4) the undifferentiated sub-type (i.e. psychotic symptoms 
are present but the criteria for the paranoid, disorganised and catatonic types are not 
met); and 5) the residual sub-type (i.e. positive symptoms are present at a low 
intensity). 
The underlying variation in the nature of schizophrenia has important 
implications on conducting research on this clinical population.  This is because the 
variations in presentation might impact fitness to plead more or less.  Therefore, 
recruiting sufficiently large enough and diverse enough samples would be imperative 
to ensure that results can be generalised and that the sample accurately reflects the 
target population. 
 
The impact of sub-types of schizophrenia on fitness to plead 
The majority of participants included in this study were diagnosed with the 
paranoid sub-type of schizophrenia which is characterised by delusions and auditory 
hallucinations.  This might have reduced the ability to generalise this study’s findings 
and understand how other sub-types might have a more or less detrimental effect on 
the capabilities that underpin fitness to plead.  For example, it would be interesting to 
investigate whether having the disorganised sub-type of schizophrenia, which is 
characterised by thought disorder, would impact fitness to plead more than having 
the paranoid sub-type.  This is because James, Duffield, Blizard and Hamilton (2001) 
found that a substantial proportion of defendants who are declared unfit to plead are 
reported to be experiencing disorganised and delusional thinking.  In addition, it 
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would be interesting to investigate how particular symptoms of schizophrenia impact 
fitness to plead.  For example, paranoid symptoms might prevent a defendant from 
instructing counsel because of his or her inability to form a trusting relationship with 
counsel, whereas hallucinations might prevent a defendant from following the 
evidence due to increased distractibility and interference. 
 
The impact of symptom severity in schizophrenia on fitness to plead 
This study predominantly recruited participants with mild symptoms of 
schizophrenia, as measured by the British Psychiatric Rating Scale (BPRS: Lukoff, 
Liberman & Nuechterlein, 1986).  Selection bias towards recruiting participants with 
mild symptoms might have occurred for several reasons.  One reason might be due to 
how participants were identified by the psychiatrist and/or clinical psychologist, in 
that it was deemed appropriate to approach a patient only if his mental state was 
stable enough to be able to sit through the testing session.  Another reason relates to 
the participants being recruited from a medium secure forensic unit, in that the 
majority of patients in the unit had long histories of mental illness, but whose acute 
symptoms were largely in remission due to assertive pharmacological intervention.  
Another plausible reason, which was based on observation, was that patients with 
more severe symptoms, particularly negative symptoms of schizophrenia, were 
poorly motivated and more likely to decline to participate. 
Setting aside the practical challenges, it would be interesting to recruit 
participants with more severe symptoms as unfitness is typically associated with 
severe symptomatology (Nicholson and Kuglar, 1991).  Indeed, several of the 
participants commented that their mental state during their actual trial was more 
disturbed than their mental state during the administration of the FTP test.  
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Consequently, the participants reflected that they might not have been able to 
maintain focus throughout the test and answer the questions as well at the time of 
their trial.  It is important to note though, that careful consideration on how to include 
participants with severe symptoms would need to be carried out as this population is 
particularly difficult to recruit and test. 
 
The impact of illness duration in schizophrenia on fitness to plead 
There was a wide range in length of illness duration between the participants 
included in this study.  However, due to the relatively small sample size and the 
majority of participants having chronic schizophrenia, investigations as to whether 
illness duration impacts performance on the FTP test could not be examined.  
Consequently, it is not known how illness duration is associated with fitness to plead. 
Fitness to plead might vary depending on illness duration, as evidence 
suggests that the deficits associated with schizophrenia change over the course of the 
disorder.  Weickert and Goldberg (2000) suggest that the cognitive deficits 
associated with schizophrenia emerge along different trajectories where: widespread 
cognitive deficits occur prior to psychotic symptoms; or cognitive deficits in 
attention, executive function and long-term memory coincide with psychotic 
symptoms and decline over time.  Sponheim et al. (2010) found several comparable 
cognitive deficits between recent-onset and chronic schizophrenia, but that other 
deficits (i.e. problem solving and episodic memory) were associated with a longer 
duration of illness.  Therefore, it would be interesting to investigate whether an 
individual with chronic schizophrenia is more likely to be considered unfit to plead 
than an individual with recent-onset schizophrenia, due to a greater number of 
deficits occurring over time. 
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Is the FTP test appropriate for use across the spectrum of schizophrenia? 
The FTP test took approximately 45 minutes to administer, despite the actual 
film footage lasting for approximately 15 minutes.  During the administration of the 
test, some of the participants were observed to lose concentration, particularly during 
the longest section of the film which lasted six minutes.  Bearing in mind that the 
participants included in this study had mild symptoms of schizophrenia, but still 
found it difficult to maintain attention, it is reasonable to assume that participants 
with acute symptoms would have certainly found it difficult to maintain attention.  
This problem is evident in the study by Pinals, Tillbrook and Mumley (2006) who 
found that only 60% of consecutively admitted patients completed the MacArthur 
Competence Assessment Tool – Criminal Adjudication (MacCAT-CA: Hoge et al., 
1999) as psychotic symptoms, mood symptoms, cognitive limitations, poor 
motivation and attempts to malinger resulted in the failure to complete the measure.  
In addition, it was found that severe thought disorganisation, irritability and 
pressured speech of the patient interfered with the examiner’s ability to present items 
without repeated interruption and to elicit coherent responses from the patient. 
Uncertainty in relation to how acutely psychotic participants would perform 
on the FTP test compared to mentally stable participants raised questions as to 
whether the FTP test is capable of assessing fitness to plead across the spectrum of 
schizophrenia.  This dilemma links back to the first section of this critical appraisal 
which reviewed some of the challenges associated with developing a standardised 
measure of fitness to plead.  Inspection of standardised measures that are currently 
available would suggest that some have been designed as a screening device, 
whereas others have been designed to provide a comprehensive evaluation.  For 
example, the Competency Screening Test (CST: Lipsitt, Lelos & McGarry, 1971) is 
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a 22-item sentence-completion task designed to screen defendants, whilst the 
Interdisciplinary Fitness Interview (IFI: Golding, Roesch & Schreiber, 1984) is a 
comprehensive assessment that assesses both legal issues and mental state in relation 
to fitness to plead.  With this in mind, the FTP test could be utilised as a 
comprehensive measure for individuals who have mild or stable symptoms of 
schizophrenia and who are capable of engaging with and enduring the assessment.  
However, this would mean that it is not suitable for acutely psychotic patients or 
screening patients.  Therefore, it might be appropriate to design a shorter measure 
which can be used to screen or measure fitness to plead in patients with acute 
symptoms of mental illness and who are less capable of tolerating long testing 
sessions.  A screening measure could also speed up assessment and be beneficial for 
criminal proceedings, as given that 20% of criminal proceedings in England and 
Wales call upon mental health expertise (Gudjonsson, 1996), this process can delay 
legal proceedings and consume resources in both criminal justice and healthcare 
settings (Akinkunmi, 2002). 
 
Summary 
The purpose of this critical appraisal was to further reflect upon areas of 
concern that emerged whilst conducting the study.  The first concern related to the 
debate over the construct of fitness to plead and its impact upon the development of 
the novel standardised measure used in this study.  This section demonstrated the 
importance of having a concise definition of fitness to plead to ensure that a 
standardised measure is reliable, valid and appropriate for use in research and clinical 
practice.  The second concern regarded the challenges associated with measuring 
fitness to plead among individuals with a diagnosis of schizophrenia.  It emphasised 
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the need for further exploration into how fitness to plead is impacted by symptom 
prevalence, symptom severity and illness duration.  It also raised questions as to 
whether the FTP test has practical utility in measuring fitness to plead across the 
spectrum of schizophrenia and whether it needs to be adapted to assess fitness to 
plead in acutely psychotic patients. 
Overall, these discussion points highlight the need for further clinically-
informed, theory-driven research into the construct of fitness to plead, how it can be 
assessed using standardised measures and how it is impacted upon by having a 
diagnosis of schizophrenia.  This is to ensure that potentially vulnerable individuals 
are protected and that the criminal justice system operates fairly during trial 
proceedings. 
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